title: patient 2 Normal

status: Public on Oct 17 2020

type: RNA

city: Changsha

first: Zheng

last: Li

state: Hunan

address: 110 Xiangya Road

country: China

institute: Central South University

description: LUAD 2N

hyb_protocol: Following fragmentation, 20 ug of cDNA were hybridized for 16 hr at 45C on Affymetrix® HTA 2.0. GeneChips were washed and stained in the Affymetrix Fluidics Station Fluidics 450.

scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G3000 7G.

data_processing: The data was normalized by Robust Multi-Array average (RMA) algorithm. Intensities of probe sets lower than 30 were reset to 30.The intensity values of individual probe sets in each sample were then displayed as the log 2 of the deviations to the calculated geometric means for that probe sets.

label: biotin

molecule: total RNA

organism: Homo sapiens

source_name: Normal lung tissues from patient 2

label_protocol: For each sample, 2µg of total RNA from each sample was used to prepare biotinylated fragmented cDNA for analysis on Affymetrix® HTA 2.0.

growth_protocol: No in vitro data

extract_protocol: Trizol extraction of total RNA was performed according to the manufacturer's instructions.

treatment_protocol: No treatment

tag: patient id

value: patient 2

tag: gender

value: Female

tag: tissue

value: lung

tag: tissue type

value: Normal

tag: histology

value: adenocarcinoma

tag: age at surgery

tag: pt stage

tag: pn stage

tag: pm stage


title: empty vector HBEC2 cells

city: Albuquerque

first: Steven

middle: A

last: Belinsky

state: NM

address: 2425 Ridgecrest Dr SE

department: Lung Cancer Program

country: USA

institute: Lovelace Respiratory Research Institute

description:
794435073_A_Grn.idat
H2

hyb_protocol: Standard Illumina hybridization protocol

scan_protocol: Standard Illumina scanning protocol

data_processing: Data were transformed using variance stablizing transformation (VST), normalized using robust spline normalization (RSN) and converted to log2 using the lumi package in R

source_name: parent  HBEC2 cell line

label_protocol: Biotinylated cRNA were prepared with the Ambion MessageAmp kit for Illumina arrays

extract_protocol: RNA extraction protocol not provided.

tag: cell line

tag: cell type

value: lung bronchial epithelium

tag: condition

value: vehicle


title: Bleomycin treated DNA-PCK deficient HBEC2 cells

description:
794435073_F_Grn.idat
H2_PKCBleo

source_name: DNA-PKC deficient HBEC2 cell line treated with Bleomycin

value: treated knockdown


title: patient 3 Lymph

description: LUAD 3L

source_name: Lymph tissues from patient 3

value: patient 3

value: Male

value: Lymph


title: patient 1 Tumor

description: LUAD 1T

source_name: Tumor tissues from patient 1

value: patient 1

value: Tumor


title: patient 3 Normal

description: LUAD 3N

source_name: Normal lung tissues from patient 3


title: patient 1 Normal

description: LUAD 1N

source_name: Normal lung tissues from patient 1


title: patient 2 Lymph

description: LUAD 2L

source_name: Lymph tissues from patient 2


title: Bleomycin treated HBEC2 cells

description:
794435073_E_Grn.idat
H2_Bleo

source_name: Bleomycin treated HBEC2 cell line

value: treated


title: DNA-PKC deficient HBEC2 cells

description:
794435073_B_Grn.idat
H2_PKC

source_name: DNA-PKC deficient HBEC2 cell line

value: knockdown


title: patient 2 Tumor

description: LUAD 2T

source_name: Tumor tissues from patient 2


title: patient 3 Tumor

description: LUAD 3T

source_name: Tumor tissues from patient 3


title: patient 1 Lymph

description: LUAD 1L

source_name: Lymph tissues from patient 1


title: Wnt11 mutant whole kidney rep5

status: Public on Oct 31 2018

type: SRA

city: Chapel Hill

first: Lori

last: O'Brien

state: North Carolina

address: 111 Mason Farm Road

department: Cell Biology and Physiology

institute: University of North Carolina at Chapel Hill

description:
Wnt11_WK_RNAseq_DiffExp.txt
M5 (RPKM)

library_source: transcriptomic

data_processing:
Sequence files were aligned using TopHat v2.0.8b and Bowtie 2.1.0.0 by the USC Epigenome Center using default parameters.
BAM files were processed to obtain RPKM values using the Partek Genomics Suite 6.6 software.
The Partek ANOVA in Partek Genomics Suite 6.6 software was utilized to find the differential expression of genes ('Differential expression analysis' function) between the two genotypes.
Genome_build: mm9
Supplementary_files_format_and_content: Tab-delimited text files contain gene identifiers, reads, RPKM, and differential expression metrics between wild type and mutant samples

organism: Mus musculus

source_name: Mouse embryonic kidney

extract_protocol:
RNA was isolated from FACS isolated cells or whole kidney using the Qiagen RNeasy micro (cells) or mini (whole kidney) kit following the manufacturer’s instructions. Cells were resuspended and vortexed in buffer RLT and whole kidneys homogenized in buffer RLT using a motorized pestle. Whole kidneys were additionally centrifuged through a QIAshredder to shear genomic DNA and reduce viscosity. The lysates were centrifuged through the provided column to isolate RNA, and the columns subsequently washed, DNase treated, washed, and eluted with RNase-free H2O.
Libraries were constructed from 20-50ng of total RNA by the USC Epigenome Center with the Illumina TruSeq RNA Library Prep Kit V2 following the manufacturer’s instructions with following modifications: End-IT repair from Epicentre was used instead of TruSeq end repair (more favorable volumes). Half of adapter-ligation was amplified for a variable number of cycles depending on input amounts. KAPA Biosystems PCR Master Mix was utilized in place of Illumina's.

treatment_protocol: To isolate nephron progenitors from E15.5 kidneys, GFP+ (Six2TGCtg+ kidneys) were identified by widefield fluorescence microscopy. Each GFP+ kidney pair were isolated, put into a 1.5ml tube, and processed individually. Kidneys were dissociated with collagenase/dispase (Roche, 10269638001) at 37oC for approximately 10-15 minutes, resuspended in PBS containing 2% FBS and 10mM EDTA, and filtered through 40 μm cell strainer (BD Falcon). GFP+ cells were isolated by sorting with a BD FACSAria II. Cells were spun down and resuspended in buffer RLT from the Qiagen RNeasy micro kit.

tag: genotype

value: Whole kidney

tag: Stage


title: Wnt11 mutant whole kidney rep4

description:
Wnt11_WK_RNAseq_DiffExp.txt
M4 (RPKM)


title: Wnt11 mutant whole kidney rep6

description:
Wnt11_WK_RNAseq_DiffExp.txt
M6 (RPKM)


title: Wnt11 mutant whole kidney rep3

description:
Wnt11_WK_RNAseq_DiffExp.txt
M3 (RPKM)


title: Bleomycin treated DNA-PCK deficient HBEC3 cells

description:
3999853039_I_Grn.idat
H3_PKCBleo

source_name: DNA-PKC deficient HBEC3 cell line treated with Bleomycin


title: Wild type whole kidney rep5

description:
Wnt11_WK_RNAseq_DiffExp.txt
WT5 (RPKM)


title: Wild type whole kidney rep4

description:
Wnt11_WK_RNAseq_DiffExp.txt
WT4 (RPKM)


title: Wild type whole kidney rep6

description:
Wnt11_WK_RNAseq_DiffExp.txt
WT6 (RPKM)


title: Wild type whole kidney rep2

description:
Wnt11_WK_RNAseq_DiffExp.txt
WT2 (RPKM)


title: Wild type whole kidney rep3

description:
Wnt11_WK_RNAseq_DiffExp.txt
WT3 (RPKM)


title: Wnt11 mutant whole kidney rep1

description:
Wnt11_WK_RNAseq_DiffExp.txt
M1 (RPKM)


title: Wnt11 mutant whole kidney rep2

description:
Wnt11_WK_RNAseq_DiffExp.txt
M2 (RPKM)


title: Bleomycin treated HBEC3 cells

description:
8381661060_H_Grn.idat
H3_Bleo

source_name: Bleomycin treated HBEC3 cell line


title: Wnt11 mutant GFP+ nephron progenitors rep3

description:
Wnt11_NP_RNAseq_DiffExp.txt
Hom6_ (RPKM)

value: Kidney nephron progenitor


title: Wnt11 mutant GFP+ nephron progenitors rep1

description:
Wnt11_NP_RNAseq_DiffExp.txt
Hom4_ (RPKM)


title: Wnt11 mutant GFP+ nephron progenitors rep2

description:
Wnt11_NP_RNAseq_DiffExp.txt
Hom5_ (RPKM)


title: Wild type GFP+ nephron progenitors rep3

description:
Wnt11_NP_RNAseq_DiffExp.txt
WT3_ (RPKM)


title: empty vector HBEC3 cells

description:
8381661060_B_Grn.idat
H3

source_name: parent HBEC3 cell line


title: Wild type GFP+ nephron progenitors rep2

description:
Wnt11_NP_RNAseq_DiffExp.txt
WT2_ (RPKM)


title: Wild type GFP+ nephron progenitors rep1

description:
Wnt11_NP_RNAseq_DiffExp.txt
WT1_ (RPKM)


title: DNA-PKC deficient HBEC3 cells

description:
8381661060_D_Grn.idat
H3_PKC

source_name: DNA-PKC deficient HBEC3 cell line


title: ∆∆Dxz_ATAC_seq_rep2

city: Cambridge

first: John

middle: Edward

last: Froberg

state: MA

address: 7 Divinity Avenue

department: Stem Cell & Regenerative Biology

institute: Harvard University

library_source: genomic

data_processing:
RNA-seq: RNA-seq reads were aligned to the cas (Xa) and mus (Xi) genomes allele-specifically using a previously published pipeline (Kung et al., Molecular Cell 2015)(GSE58242). Following alignment, gene expression levels for each gene were defined using HOMER. Differential expression and fold changes between conditions were calculated using DESeq2. We plotted the cumulative distributions of fold changes for autosomal and X-linked genes and evaluated the significance of any differences between the distributions of the fold changes using the Kolmogorov-Smirnov (KS) test. To examine allele-specific expression from the Xa and the Xi, we summed together allelic reads across both biological replicates and filtered for genes with at least 12 allelic reads in both wild-type and Dxz4∆/∆:FirreXi∆/+and fpm > 0 in all replicates. We also used RNA-seq done in pure hybrid mus or cas fibroblasts to identify and eliminate genes that have incorrect SNP information. We defined escapee genes in a particular condition as genes where at least 10% of allelic reads came from the Xi in either replicate of that condition. We plotted the distribution of expression levels from the Xi (Xi/(Xi+Xa) read counts) for all genes passing our filtered for each replicate. We evaluated the significance in differences of the mean expression level from the Xi using the Wilcoxon Signed Rank Test with Bonferroni correction for multiple hypothesis testing.
ATAC-seq: Attack seq alignment to mm9 was performed exactly as ChIP-seq alignment was performed in (Minajigi et al., Science 2015) (GSE67516). Peaks were called using macs2 with default parameters. Biallelic peaks were identified as peaks with at least 10 alleleic reads in a sample and an Xi:Xa ratio greater than 1/3. Xi-specific peaks were defined as peaks with at least 10 allelic reads and a Xi:Xa ratio less than 1/3. To test whether Xi-specific peaks in wild-type are “restored” (that is: acquire appreciable accessibility on the Xi) in either the Dxz4 or Firre deletion, we plot the wild-type Xa reads on the x-axis and the deletion Xi reads on the y-axis and identify peaks where the deletion Xi/wild-type Xa ratio is greater than ½ (these are peaks where the deletion accessibility level reaches at least half the wild-type accessibility ratio). We also examine the biallelic peaks and plot the wild-type Xi reads on the x-axis and the deletion Xi reads on the y-axis to determine whether the accessibility on the Xi changes for the peaks that are bi-allelic in wild-type.
Hi-C: Hi-C alignment to mm9 was performed according to the method of (Minajigi et al., Science 2015)(GSE67516) The allele-specific Hi-C reads were filtered for quality and uniqueness with HOMER. Custom scripts were used to convert HOMER tag directories into the format accecpted by Juicebox; contact maps were generated using the Juicer tools ‘pre’ command. All Hi-C contact maps visualized in this study are KR-normalized contact maps generated by Juicebox.
Hi-C^2: Reads of each pair were individually mapped to the mus and cas reference genomes using novoalign and merged into Hi-C summary files and filtered using HOMER as previously described (Minajigi et al., Science 2015). For the chrX:70,370,161-71,832,975 captures, 3-4% of mapped and paired reads fell within the target region (0.05% expected based on size of capture region versus genome) and for the chrX:71,832,976-73,511,687 captures, 1-2% of mapped and paired reads fell within the target region (0.06% expected based on size of capture region versus genome). To avoid computational complexities arising from normalization of sparse, non-enriched regions in the Hi-C contact map, only Hi-C interactions falling within the capture region were analyzed further. For each capture, a custom script was used to pull out the filtered Hi-C interactions falling within the target region from the HOMER tag directories. Hi-C contact maps of the capture regions were then generated from these HOMER tags using the ‘pre’ command of Juicer tools. The resulting Hi-C contact maps in .hic format were visualized and normalized with the ‘Coverage (Sqrt)’ option in Juicebox.
4C: 4C analysis was performed using the previously published pipeline in (Chu et al., NSMB 2017) (GSE69887).
Genome_build: mm9
Supplementary_files_format_and_content: bedGraph files display fragment counts per million reads passing filter for 4C experiments. bigWig files display fpm-normalized ATAC-seq coverage. .hic files can be used to display and generate Hi-C contact maps using the Juicebox toolkit. For bedGraph and bigWig files, "comp" tracks are generated using all unique reads, "mus" tracks are generated using mus-specific reads, "cas" tracks are generated using cas-specific reads and "reps" tracks are generated using non-unique reads (reads with multiple alignments are randomly assigned to one position). genetable*.xlsx files are generated from homer and contain fragment count information for each gene in each experiment.

molecule: genomic DNA

source_name: mESC

extract_protocol: 50,000 cells were washed in cold PBS and lysed in cold lysis buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.1% IGEPAL CA-630) containing proteinase inhibitor cocktail (Roche). Nuclei were resuspended in 1X TD Buffer (Illumina FC-121-1030) and 2.5uL of Tn5 Transposase (Illumina FC-121-1030) were added. Transposition reaction was performed at 37°C for 30min, and DNA was purified using a Qiagen MinElute Kit. DNA libraries were amplified for a total of 8 cycles. Libraries were assessed for quality control on the BioAnalyzer 2100 (Aglient) to ensure nucleosomal phasing and complexity. Sequencing was performed on the HiSeq 2000 (Illumina), using 50 bp paired-end reads.

tag: strain

value: CAST/Ei x 129/Sv/Jae

value: mESC (Tsix-stop)


title: FirreXi∆/+_ATAC_seq_rep2

value: FirreXi{delta}/+


title: ∆Dxz:∆Firre_ATAC_seq_rep2


title: FirreXi∆/+_ATAC_seq_rep3


title: TST_ATAC_seq_rep3

value: WT


title: Xist+Pfib_Tg4C

data_processing:
Library strategy: 4C-seq
RNA-seq: RNA-seq reads were aligned to the cas (Xa) and mus (Xi) genomes allele-specifically using a previously published pipeline (Kung et al., Molecular Cell 2015)(GSE58242). Following alignment, gene expression levels for each gene were defined using HOMER. Differential expression and fold changes between conditions were calculated using DESeq2. We plotted the cumulative distributions of fold changes for autosomal and X-linked genes and evaluated the significance of any differences between the distributions of the fold changes using the Kolmogorov-Smirnov (KS) test. To examine allele-specific expression from the Xa and the Xi, we summed together allelic reads across both biological replicates and filtered for genes with at least 12 allelic reads in both wild-type and Dxz4∆/∆:FirreXi∆/+and fpm > 0 in all replicates. We also used RNA-seq done in pure hybrid mus or cas fibroblasts to identify and eliminate genes that have incorrect SNP information. We defined escapee genes in a particular condition as genes where at least 10% of allelic reads came from the Xi in either replicate of that condition. We plotted the distribution of expression levels from the Xi (Xi/(Xi+Xa) read counts) for all genes passing our filtered for each replicate. We evaluated the significance in differences of the mean expression level from the Xi using the Wilcoxon Signed Rank Test with Bonferroni correction for multiple hypothesis testing.
ATAC-seq: Attack seq alignment to mm9 was performed exactly as ChIP-seq alignment was performed in (Minajigi et al., Science 2015) (GSE67516). Peaks were called using macs2 with default parameters. Biallelic peaks were identified as peaks with at least 10 alleleic reads in a sample and an Xi:Xa ratio greater than 1/3. Xi-specific peaks were defined as peaks with at least 10 allelic reads and a Xi:Xa ratio less than 1/3. To test whether Xi-specific peaks in wild-type are “restored” (that is: acquire appreciable accessibility on the Xi) in either the Dxz4 or Firre deletion, we plot the wild-type Xa reads on the x-axis and the deletion Xi reads on the y-axis and identify peaks where the deletion Xi/wild-type Xa ratio is greater than ½ (these are peaks where the deletion accessibility level reaches at least half the wild-type accessibility ratio). We also examine the biallelic peaks and plot the wild-type Xi reads on the x-axis and the deletion Xi reads on the y-axis to determine whether the accessibility on the Xi changes for the peaks that are bi-allelic in wild-type.
Hi-C: Hi-C alignment to mm9 was performed according to the method of (Minajigi et al., Science 2015)(GSE67516) The allele-specific Hi-C reads were filtered for quality and uniqueness with HOMER. Custom scripts were used to convert HOMER tag directories into the format accecpted by Juicebox; contact maps were generated using the Juicer tools ‘pre’ command. All Hi-C contact maps visualized in this study are KR-normalized contact maps generated by Juicebox.
Hi-C^2: Reads of each pair were individually mapped to the mus and cas reference genomes using novoalign and merged into Hi-C summary files and filtered using HOMER as previously described (Minajigi et al., Science 2015). For the chrX:70,370,161-71,832,975 captures, 3-4% of mapped and paired reads fell within the target region (0.05% expected based on size of capture region versus genome) and for the chrX:71,832,976-73,511,687 captures, 1-2% of mapped and paired reads fell within the target region (0.06% expected based on size of capture region versus genome). To avoid computational complexities arising from normalization of sparse, non-enriched regions in the Hi-C contact map, only Hi-C interactions falling within the capture region were analyzed further. For each capture, a custom script was used to pull out the filtered Hi-C interactions falling within the target region from the HOMER tag directories. Hi-C contact maps of the capture regions were then generated from these HOMER tags using the ‘pre’ command of Juicer tools. The resulting Hi-C contact maps in .hic format were visualized and normalized with the ‘Coverage (Sqrt)’ option in Juicebox.
4C: 4C analysis was performed using the previously published pipeline in (Chu et al., NSMB 2017) (GSE69887).
Genome_build: mm9
Supplementary_files_format_and_content: bedGraph files display fragment counts per million reads passing filter for 4C experiments. bigWig files display fpm-normalized ATAC-seq coverage. .hic files can be used to display and generate Hi-C contact maps using the Juicebox toolkit. For bedGraph and bigWig files, "comp" tracks are generated using all unique reads, "mus" tracks are generated using mus-specific reads, "cas" tracks are generated using cas-specific reads and "reps" tracks are generated using non-unique reads (reads with multiple alignments are randomly assigned to one position). genetable*.xlsx files are generated from homer and contain fragment count information for each gene in each experiment.

source_name: fibroblast

extract_protocol: We previously developed a modified 4C protocol (Chu et al., NSMB 2017)  to examine chromatin conformation from repetitive viewpoints. Our protocol has several advantages over existing 4C profiles: 1.) It sequences the genomic region amplified by the 4C primers, ensuring that on-target priming events can be identified and filtered from numerous off-target priming events 2.) Sequencing the viewpoint allows every read to be assigned to a particular allele if the viewpoint is near a variant, 3.) We use a random barcode to identify PCR duplicates, which previously has not been possible in 4C experiments. We performed our modified 4C using the protocol and analysis pipeline previously described for viewpoints within PAR-TERRA repeats (Chu et al., 2017). We used it for several viewpoints within Firre and Dxz4. Some viewpoints were in the core tandem repeats. For these viewpoints, we use the read outside the viewpoint for allelic determination. Others were in unique regions near the tandem repeats; for these we could use known variants to assign every read to the Xa or the Xi. We performed our analysis in two fibroblast lines, one where the mus X is inactive (mus Xi cas Xa), the other where the cas X is inactive (mus Xa cas Xi).

value: male immortalized fibroblast

value: Xist Tg


title: WT_Xyfib_Tg4C


title: TST_ATACseq_rep2


title: XPDXZ4.4fib_Tg4C

value: Xist+Dxz4 Tg


title: ∆Dxz:∆FirreRNAseq_rep2

description:
JOa36-4
TSTvsDFH12wPureLines.genetable.xlsx

molecule: polyA RNA

extract_protocol: Total RNA was isolated from 2-5 million trypsinized cells using trizol extraction. polyA+ mRNA was isolated using the NEBNext NEBNext® Poly(A) mRNA Magnetic Isolation Module using 5 ug of total RNA as input. Isolated mRNA was reverse-transcribed using Superscript III and actinomycin D to inhibit template switching. Second-strand synthesis was performed using the NEBNext Ultra Directional RNA Second Strand Synthesis Module. Library preparation and NEBNext® ChIP-Seq Library Prep Master Mix Set for Illumina. A USER enzyme treatment was performed following adaptor ligation to specifically degrade the second strand and allow a stranded analysis. Libraries were amplified for 10-15 cycles of PCR using Q5 polymerase and NEBNext multiplex oligos.


title: TSTRNAseq_rep2

description:
JOa36-3
TSTvsDFH12wPureLines.genetable.xlsx


title: ∆∆Dxz_ATAC_seq_rep1


title: ∆Dxz:∆Firre_ATAC_seq_rep1


title: FirreXi∆/+_ATAC_seq_rep1


title: genomic DNA from HBEC2 cells [H2_Bleo]

type: genomic

description:
H2Bleo Signal_A (unmethylated signal)
H2Bleo Signal_B (methylated signal)
Bleomycin treated HBEC2 cell line

hyb_protocol: bisulphite converted DNA was amplified, fragmented and hybridized to Illumina MethylationEPIC Beadchip using standard Illumina protocol

scan_protocol: Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner settings

data_processing: Data were normalized and background substracted using Bioconductor methylumi package noob procedure in R

label: Cy5 and Cy3

label_protocol: Standard Illumina Protocol

extract_protocol: genomic DNA was treated with proteinase K, digested with Rnase and phenol chloroform extracted

value: lung bronchial epithelium


title: genomic DNA from HBEC2 cells [H2]

description:
H2 Signal_A (unmethylated signal)
H2 Signal_B (methylated signal)
parent  HBEC2 cell line

source_name: parent  HBEC2 cell line

value: vehicle


title: d10RNAseq_rep1

description:
TC_RNA_4
TimecourseWPureLines.genetable_renamed.xlsx

tag: time


title: d7RNAseq_rep1

description:
TC_RNA_3
TimecourseWPureLines.genetable_renamed.xlsx


title: d0RNAseq_rep1

description:
TC_RNA_1
TimecourseWPureLines.genetable_renamed.xlsx


title: d3RNAseq_rep2

description:
TC_RNA_6
TimecourseWPureLines.genetable_renamed.xlsx


title: d0RNAseq_rep2

description:
TC_RNA_5
TimecourseWPureLines.genetable_renamed.xlsx


title: ∆Dxz:∆FirreRNAseq_rep1

description:
JOa36-2
TSTvsDFH12wPureLines.genetable.xlsx


title: d7RNAseq_rep2

description:
TC_RNA_7
TimecourseWPureLines.genetable_renamed.xlsx


title: d3RNAseq_rep1

description:
TC_RNA_2
TimecourseWPureLines.genetable_renamed.xlsx


title: genomic DNA from HBEC3 cells [H3_PKCBleo]

description:
H3PKCBleo Signal_A (unmethylated signal)
H3PKCBleo Signal_B (methylated signal)
DNA-PKC knockdown HBEC3 cell line treated with Bleomycin

value: treated knockdown


title: d10RNAseq_rep2

description:
TC_RNA_8
TimecourseWPureLines.genetable_renamed.xlsx


title: genomic DNA from HBEC3 cells [H3_PKC]

description:
H3PKC Signal_A (unmethylated signal)
H3Bleo Signal_B (methylated signal)
DNA-PKC knockdown HBEC3 cell line

source_name: DNA-PKC knockdown HBEC3 cell line


title: genomic DNA from HBEC3 cells [H3]

description:
H3 Signal_A (unmethylated signal)
H3 Signal_B (methylated signal)
parent HBEC3 cell line


title: genomic DNA from HBEC2 cells [H2_PKC]

description:
H2PKC Signal_A (unmethylated signal)
H2Bleo Signal_B (methylated signal)
DNA-PKC knockdown HBEC2 cell line

source_name: DNA-PKC knockdown HBEC2 cell line


title: genomic DNA from HBEC2 cells [H2_PKCBleo]

description:
H2PKCBleo Signal_A (unmethylated signal)
H2PKCBleo Signal_B (methylated signal)
DNA-PKC knockdown HBEC2 cell line treated with Bleomycin


title: genomic DNA from HBEC3 cells [H3_Bleo]

description:
H3Bleo Signal_A (unmethylated signal)
H3Bleo Signal_B (methylated signal)
Bleomycin treated HBEC3 cell line


title: Wild type whole kidney rep1

description:
Wnt11_WK_RNAseq_DiffExp.txt
WT1 (RPKM)


title: ESCC_GE043B_Sty

city: Bethesda

first: Howard

last: Yang

state: MD

address: 37 CONVENT DR, Room 5120

department: CCR

institute: NCI

description: Hybridized to Affymetrix SNP array

hyb_protocol: DNA was restriction digested, PCR amplified, fragmented, labeled and hybridized to each array according to the manufacturer's instructions.

scan_protocol: The Arrays were then washed using Affymetrix fluidics stations, and scanned using the Gene Chip Scanner 3000.

data_processing: The array image was acquired using Affymetrix GeneChip®Operating Software (GCOS version1.4). Genotype calls were generated by using GTYPE4.1. The raw date[file] were loaded using R/biocunductor and aroma. Affymetrix.For more details, go to htpp://www.aroma-project.org/. We used the CRMA function implemented in the Aroma to preprocess and applied CBS method for segmentation. We combined the segmentation results from two platforms, and imported to Nexus Copy Number 6.1 followed the manual ( www. Biodiscovery.com). We used Q-Bound cut off at 0.5 and G-Score cut off at 1.0. to identify the focal regions of amplification and deletion with FDR q-value 0.25 for copy number using GISTIC 2.0 as recommended.

label: Biotin

source_name: whole blood

label_protocol: As per manufacturer (Affymetrix)

extract_protocol: tumor DNA was isolated from frozen tummor tissue using the Allprep Kit (Qiagen) per the manufacturer's instruction. Germline DNA was isolated from the same patient's venous blood. DNA quality and quantity were determined using NanoDrop 2000 (Thermo Scientific).

tag: disease state

value: ESCC

tag: case id

value: blood from esophageal squamous cell carcinoma patient


title: ESCC_GE038T_Sty

description: Hybridized to Affymetrix SNP array

source_name: tumor tissue

value: esophageal squamous cell carcinoma tissue


title: ESCC_GE040T_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE037T_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE043T_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE036T_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE035T_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE038B_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE036B_Sty

description: Hybridized to Affymetrix SNP array


title: TST_ATACseq_rep1


title: TSTRNAseq_rep1

description:
JOa36-1
TSTvsDFH12wPureLines.genetable.xlsx


title: ESCC_GE046T_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE042B_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE037B_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE035B_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE040B_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE046B_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE042T_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE044T_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE044B_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE033T_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE033B_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE032T_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE034B_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE032B_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE031T_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE030T_Sty

description: Hybridized to Affymetrix SNP array


title: Biofilms formed in LB on borosilicate glass discs 2

first: Tsute

last: Chen

address: 245 First Street

department: Microbiology

institute: The Forsyth Institute

description: used in DESeq file plusCipro.vs.PABiofilm.txt

data_processing:
Following Illumina sequencing, data were de-multiplexing with CASAVA
Reads were mapped to P. aeruginosa PAO1 genome with Bowtie
Forward and reversed reads were seperated with SMAtools
Read count per gene were calculated with a custom-Perl script
Read count tables were subject to DESeq for different gene expression analysis
Genome_build: NC_002516.2
Supplementary_files_format_and_content: tab-delimited data generated by DESeq

organism: Pseudomonas aeruginosa

source_name: Lab culture

growth_protocol: An 18-hour culture of P. aeruginosa PAO1 was grown in Luria-Bertani (LB) broth at 37°C.

extract_protocol:
RNA was isolated from untreated and persister cells using the RNeasy Kit (QIAgen) according to manufacturer’s instructions and treated twice with TURBO DNase (Ambion, Grand Island, NY) to remove any contaminating DNA (5, 6).  Ribosomal RNA was depleted using the Ribo-Zero Magnetic kit (Epicentre, Madison, WI)
Directional library was generated using the NEXTflex directional RNA-seq kit (Bioo Scientific, Austin, TX)

treatment_protocol: Persister cells (plusCiprolLarge) were isolated by centrifuging the culture and washing with 0.85% NaCl three times before incubating the cells with ciprofloxacin (50 µg/ml) in 0.85% NaCl (persister, plusCiproLarge) or 0.85% NaCl alone (stationary, minusCiproLarge) for 3.5 hours. Following incubation, the cells were again washed three times with 0.85% NaCl and plated on LB agar. The 18-hour culture was used to inoculate fresh LB which was incubated until the OD600 reached 0.5 (planktonic). Biofilms were formed in LB on borosilicate glass discs as described previously.  Each treatment condition was performed twice.

value: Biofilms

tag: protocol

value: LB on borosilicate glass discs


title: Planktonic cells - cells grown in LB 2

description: used in DESeq file plusCipro.vs.PAPlanktonic.txt

value: Planktonic cells

value: LB


title: Planktonic cells - cells grown in LB 1


title: Biofilms formed in LB on borosilicate glass discs 1


title: Stationary cells - cells not treated with ciprofloxacin 1

description: used in DESeq file plusCipro.vs.minusCipro.txt

value: Stationary cells

value: ciprofloxacin


title: Stationary cells - cells not treated with ciprofloxacin 2


title: ESCC_GE034T_Sty

description: Hybridized to Affymetrix SNP array

tag: tissue


title: ESCC_GE030B_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE029T_Sty

description: Hybridized to Affymetrix SNP array


title: Persister cells - cells treated with ciprofloxacin 2

description: used in DESeq files plusCipro.vs.minusCipro.txt, plusCipro.vs.PAPlanktonic.txt, and plusCipro.vs.PABiofilm.txt

value: Persister cells


title: Cldnk_GFP_MUT

city: Stanford

first: Harini

last: Iyer

state: California

address: 279 Campus Drive, B300 Beckman Center

department: Developmental Biology

institute: Stanford University

description: the paired end R1 and R2 do not correspond to a single sample, GEO record represent merged/two independent biological replicates

data_processing:
Trimmed, paired end reads from each sample were mapped to zebrafish reference genome using CLC Genomics Workbench 11.0
Danio rerio reference genome and transcriptome was downloaded from CLC Genomics workbench 11.0
Differential expression analysis was performed by comparing mapped control and rraga mutant reads using CLC Genomics Workbench 11.0 while controling for two independent experiments
Gene ontology was performed using zebrafish annotations file (v1.4) downloaded from Gene Ontology Consortium
Genome_build: GRCz11
Supplementary_files_format_and_content: Fold change

organism: Danio rerio

source_name: Oligodendrocytes

extract_protocol:
Cldnk:GFP cells were isolated from wildtype and rraga mutant samples by FACS sorting.
Libraries were prepared using Illumina NextSeq Mid

value: TL (Tupfel long fin)

tag: developmental stage

value: 5 days post fertilization

value: rraga mutant


title: Cldnk_GFP_WT

value: Wild type


title: ESCC_GE025T_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE028B_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE026B_Sty

description: Hybridized to Affymetrix SNP array


title: Persister cells - cells treated with ciprofloxacin 1


title: ESCC_GE026T_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE028T_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE025B_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE027B_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE027T_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE029B_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE031B_Sty

description: Hybridized to Affymetrix SNP array


title: ESCC_GE024B_Sty

description: Hybridized to Affymetrix SNP array


title: Jukat-TET-On_Tax-B_Dox+_rep1

city: Kurashiki

first: Tadasuke

last: Naito

state: Okayama

address: 577 Matsushima

country: Japan

institute: Kawasaki Medical School

description: Jurkat-TET-On cells were transfected with pTRE3G-Tax-B, and then were treated with Dox for protein induction

hyb_protocol: 600 ng of Cy3-labelled cRNA (specific activity >6.0 pmol Cy3/ug cRNA) was fragmented at 60°C for 30 minutes in a reaction volume of 25 ul containing 1x Agilent fragmentation buffer and 2x Agilent blocking agent following the manufacturers instructions. On completion of the fragmentation reaction, 25 ul of 2xGE Agilent hybridization buffer HI-RPM was added to the fragmentation mixture and hybridized to Agilent SurePrint G3 Human GE 8x60K V2 Microarrays (G4851B) for 17 hours at 65°C in a rotating Agilent hybridization oven.  After hybridization, microarrays were washed 1 minute at room temperature with GE Wash Buffer 1 (Agilent) and 1 minute with 37°C GE Wash buffer 2 (Agilent), then dried immediately by brief centrifugation.

scan_protocol: Slides were scanned immediately after washing on the Agilent DNA Microarray Scanner (G2505C) using one color scan setting for 8x60k array slides (Scan Area 61x21.6 mm, Scan resolution 3um, Dye channel is set to Green).

data_processing: The scanned images were analyzed with Feature Extraction Software 11.0.1.1 (Agilent) using default parameters (protocol GE1-1100_Jul11 and Grid: 039494_D_F_20140813) to obtain background subtracted and spatially detrended Processed Signal intensities.  Features flagged in Feature Extraction as Feature Non-uniform outliers were excluded.

source_name: Jukat-TET-On cell line

label_protocol: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.1 ug RNA using the One-Color Low Input Quick Amp Labeling Kit (Agilent) according to the manufacturer's instructions, followed by RNAeasy Mini Kit column purification (QIAGEN).  Dye incorporation and cRNA yield were checked with the NanoDrop Spectrophotometer and the Agilent 2100 Bioanalyzer.

extract_protocol: RNA was prepared using the RNAeasy Mini Kit column purification (QIAGEN) following the manufacturer's recommendations. RNA was quantified using a NanoDrop spectrophotometer and quality was monitored with 1% Agarose/Formaldehyde gel electrophoresis.

tag: transfected plasmid

tag: induced protein

value: HTLV-1 Tax-B

tag: agent

value: Doxycycline


title: Jukat-TET-On_Tax-B_Dox-_rep1

description: Jurkat-TET-On cells were transfected with pTRE3G-Tax-B, and then were treated with buffer for non-induction control

value: Non-treated


title: Jukat-TET-On_HBZ-B_Dox-_rep3

description: Jurkat-TET-On cells were transfected with pTRE3G-HBZ-B, and then were treated with buffer for non-induction control


title: Jukat-TET-On_HBZ-B_Dox-_rep2


title: ESCC_GE024T_Sty

description: Hybridized to Affymetrix SNP array

value: ESCC


title: Jukat-TET-On_HBZ-A_Dox+_rep3

description: Jurkat-TET-On cells were transfected with pTRE3G-HBZ-A, and then were treated with Dox for protein induction

value: HTLV-1 HBZ-A


title: Jukat-TET-On_HBZ-B_Dox-_rep1


title: Jukat-TET-On_HBZ-B_Dox+_rep1

description: Jurkat-TET-On cells were transfected with pTRE3G-HBZ-B, and then were treated with Dox for protein induction

value: HTLV-1 HBZ-B


title: Jukat-TET-On_HBZ-B_Dox+_rep3


title: Jukat-TET-On_Tax-A_Dox-_rep1

description: Jurkat-TET-On cells were transfected with pTRE3G-Tax-A, and then were treated with buffer for non-induction control


title: Jukat-TET-On_HBZ-B_Dox+_rep2


title: Jukat-TET-On_Tax-A_Dox+_rep1

description: Jurkat-TET-On cells were transfected with pTRE3G-Tax-A, and then were treated with Dox for protein induction

value: HTLV-1 Tax-A


title: Jukat-TET-On_HBZ-A_Dox+_rep2


title: Jukat-TET-On_empty_Dox+_rep3

description: Jurkat-TET-On cells were transfected with pTRE3G-IRES-empty, and then were treated with Dox for non-induction control


title: Jukat-TET-On_HBZ-A_Dox-_rep3

description: Jurkat-TET-On cells were transfected with pTRE3G-HBZ-A, and then were treated with buffer for non-induction control


title: Jukat-TET-On_empty_Dox-_rep1

description: Jurkat-TET-On cells were transfected with pTRE3G-IRES-empty, and then were treated with bufffer for non-induction control


title: Jukat-TET-On_empty_Dox+_rep2


title: Jukat-TET-On_HBZ-A_Dox+_rep1


title: Jukat-TET-On_empty_Dox-_rep3


title: Jukat-TET-On_empty_Dox+_rep1


title: Jukat-TET-On_empty_Dox-_rep2


title: Jukat-TET-On_HBZ-A_Dox-_rep2


title: Jukat-TET-On_HBZ-A_Dox-_rep1


title: PEK1_pmt2_1

city: Singapore

first: Guillaume

last: Thibault

state: Outside the US or Canada

address: 60 Nanyang Drive

department: School of Biological Sciences

country: Singapore

institute: Nanyang Technological University

hyb_protocol: 3 ug of fragmented and labeled cDNA were hybridized for 16 hrs at 45C on GeneChip C elegans ST arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 450

scan_protocol: GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G

data_processing:
Data was processed using RMA
Normalized differential gene expression files on Series record
The resulting CHP files are generated by the Affymetrix Tiling Analysis Software (v. 3.0), where gene expression of untreated samples are compared against the pmt-2(RNAi) treated samples.

organism: Caenorhabditis elegans

source_name: Larval stage L1 to young adult, RNAi

label_protocol: Biotinylated cDNA was prepared using the Affymetrix WT PLUS Reagent Kit from 300ng total RNA

growth_protocol: Synchronised C. elegans at L1 stage were grown on normal growth media with 25µg/mL carbenicillin and 1mM IPTG and harvested when most of the animals had reached young adulthood.

extract_protocol: RNA was extracted with Trizol and purified with QIAGEN RNeasy Columns

treatment_protocol:
Worm growth medium contains 25µg/mL carbenicillin and 1mM IPTG, grown from synchronised L1 stage to L4/young adult stage)
25µg/mL carbenicillin, 1mM IPTG, 25µg/mL Tunicamycin

tag: genotype/variation

value: PEK1 knockout

value: young adult

tag: RNAi


title: PMT2KO_L4440_1

description: control for pmt-2 RNAi

source_name: Larval stage L1 to young adult, knockout

value: PMT2 knockout


title: PMT2KO_L4440_3

description: control for pmt-2 RNAi


title: PEK1_L4440_3

value: pL4440 (Empty vector)


title: PMT2KO_L4440_2

description: control for pmt-2 RNAi


title: PEK1_L4440_2


title: IRE1_pmt2_2

value: IRE1 knockout


title: IRE1_pmt2_1


title: PEK1_pmt2_2


title: PEK1_pmt2_3


title: ATF6_pmt2_2

value: ATF6 knockout


title: IRE1_pmt2_3


title: ATF6_pmt2_3


title: ATF6_pmt2_1


title: N2_TM_3

description: positive control for UPR activation

treatment_protocol:
Worm growth medium contains 25µg/mL carbenicillin and 1mM IPTG, grown from synchronised L1 stage to L4/young adult stage). Harvested young adult worms were treated with 25µg/mL tunicamycin for 4 hours in M9 buffer.
25µg/mL carbenicillin, 1mM IPTG, 25µg/mL Tunicamycin

value: N2 wild type

tag: drug treatment

value: Tunicamycin


title: IRE1_L4440_3


title: N2_TM_2

description: positive control for UPR activation


title: ATF6_L4440_3


title: IRE1_L4440_1


title: ATF6_L4440_1


title: N2_TM_1

description: positive control for UPR activation


title: N2_pmt2_1

source_name: Larval stage L1 to young adult, tunicamycin


title: ATF6_L4440_2


title: N2_L4440_3


title: N2_pmt2_3


title: N2_pmt2_2


title: N2_L4440_2


title: N2_L4440_1


title: A375WT_rep1

city: Taipei

first: Yi-Shuan

last: Sheen

address: 7 Chun-Shan South Road

department: Dermatology

country: Taiwan

institute: Natioanl Taiwan University Hospital

description: biological replicate 1 of 2

hyb_protocol: Fluorescent targets were hybridized to the Phalanx Human OneArray v6.1 with Phalanx hybridization buffer using Phalanx Hybridization System.

scan_protocol: The scanned images were analyzed with Agilent Scanner and processing by GenePix software 4.1 to obtain background subtracted and spatially detrended Processed Signal intensities.

data_processing: Data were analyzed with the Rosetta Resolver System software (Rosetta Biosoftware, USA). The Rosetta Resolver System Error Model was used to calculate the normalized intensities, CV, log2 ratio and p-value (differential expressed). Briefly, probes whose flags were -50 within all arrays were excluded; replicated probes within one chip were averaged; intensities were normalized by median scaling and taking the mean intensities.

source_name: A375 melanoma cells

label_protocol: Cyanine-5 (Cy5) labeled cRNA was prepared from 0.5 ug RNA using the One-Color Low RNA Input Linear Amplification PLUS kit (Agilent) according to the manufacturer's instructions, followed by RNeasy column purification (QIAGEN, Valencia, CA). Dye incorporation and cRNA yield were checked with the NanoDrop ND-1000 Spectrophotometer.

growth_protocol: BRAF-V600E mutated A375 melanoma cells were obtained from the American Type Culture Collection and maintained in Dulbecco’s modified Eagle medium (DMEM) (Life Technologies Inc., Carlsbad, CA), supplemented with 10% fetal bovine serum (FBS) (Gibco, Invitrogen Corporation, Carlsbad, CA) and 1% antibiotics (Gibco).

extract_protocol: Total RNA extracted using Trizol following manufacturer's instructions

treatment_protocol: A375 cells were cultured by chronically exposing to increasing concentrations of dabrafenib and trametinib (1 nM Dab and 0.1 nM Tra, 10 nM Dab and 1 nM Tra, 100 nM Dab and 10 nM Tra).

tag: cell line

tag: cell type

value: melanoma cells


title: A375WT_rep2

description: biological replicate 2 of 2


title: A375DTR#1_rep1

description: biological replicate 1 of 2

source_name: Acquired dabrafenib and trametinib resistant A375 cells


title: A375DTR#1_rep2

description: biological replicate 2 of 2


title: MSA207_P19_ETIFENIN 1_uM 6_hours 581-2-1

city: Tempe

first: Ben

last: Readhead

state: AZ

address: 797 E. Tyler Street

institute: ASU-Banner Neurodegenerative Disease Research Center

description: 24 hiPSC-derived NPCs and 8 CCLs were used (total: 32 cell lines). Each 96-well plate included: A1 empty well, 12 vehicle wells, and 2 positive control wells (in duplicate) per cell line (i.e., per plate). The remaining 79 wells were used for test compounds: a) phase 1 had 6/79 drugs from pilot, and 73/79 phase 1 test compounds, b) phase 2 had 6 pilot drugs re-tested, 6/73 phase 1 drugs re-tested, and 67/79 phase 2 compounds. 135 unique compounds were tested.

hyb_protocol: PCR amplicon of each gene is hybridized to barcoded Luminex beads. The barcode incorporated in each amplicon is complementary to a barcode on a Luminex bead, ensuring that each gene from the original lysate mRNA is represented by an amplicon bound to a specific bead.

scan_protocol: Luminex scanners detect individual beads by color, then measure the fluorescent intensity of the SAPE molecules attached to the biotin label on each amplicon-bound bead

data_processing: Raw intensity measurements are deconvoluted to provide intensity values for each landmark gene (the 978 directly measured features). Data is then normalized using a calibration curve based on invariant gene sets, and then quantile normalized.

label_protocol: mRNA is reverse transcribed and the cDNA product PCR amplified using primers that contain contiguous sequence (barcode) complementary to each L1000 gene; in addition, the upstream primer is biotinylated to enable identification of amplicon-bound beads.

extract_protocol: Cells were lysed with cell lysis buffer (110 µL per well), and stored at -80⁰C

tag: perturbagen

value: ETIFENIN

tag: cell id

tag: dosage

tag: batch

tag: duration

tag: perturbation type

value: test

tag: well id

tag: plate id


title: MSA207_P15_ETHOXZOLAMIDE 0_uM 6_hours 581-2-1

value: ETHOXZOLAMIDE


title: MSA207_P13_DMSO NA 6_hours 581-2-1

value: DMSO

value: vehicle


title: MSA207_P16_ETHOXZOLAMIDE 0_uM 6_hours 3121-2-1


title: MSA207_P14_DMSO NA 6_hours 3121-2-1


title: MSA207_P21_MOCLOBEMIDE 10_uM 6_hours 581-2-1

value: MOCLOBEMIDE


title: MSA207_P10_CETOCYCLINE' 'A-13428' 0.3_uM 6_hours 3121-2-1

value: CETOCYCLINE' 'A-13428'


title: MSA207_P18_GLIPIZIDE 0_uM 6_hours 3121-2-1

value: GLIPIZIDE


title: MSA207_P22_MOCLOBEMIDE 10_uM 6_hours 3121-2-1


title: MSA207_P24_Nimodipine 1.34_uM 6_hours 3121-2-1

value: Nimodipine


title: MSA207_P20_ETIFENIN 1_uM 6_hours 3121-2-1


title: MSA207_P23_Nimodipine 1.34_uM 6_hours 581-2-1


title: MSA207_P12_BUFLOMEDIL HYDROCHLORIDE 1_uM 6_hours 3121-2-1

value: BUFLOMEDIL HYDROCHLORIDE


title: MSA207_P09_CETOCYCLINE' 'A-13428' 0.3_uM 6_hours 581-2-1


title: MSA207_P11_BUFLOMEDIL HYDROCHLORIDE 1_uM 6_hours 581-2-1


title: MSA207_P17_GLIPIZIDE 0_uM 6_hours 581-2-1


title: MSA207_P07_VATALANIB 1_uM 6_hours 581-2-1

value: VATALANIB


title: MSA207_P06_BUPROPION HYDROCHLORIDE 0.3_uM 6_hours 3121-2-1

value: BUPROPION HYDROCHLORIDE


title: MSA207_P08_VATALANIB 1_uM 6_hours 3121-2-1


title: MSA207_P04_DMSO NA 6_hours 3121-2-1


title: MSA207_P05_BUPROPION HYDROCHLORIDE 0.3_uM 6_hours 581-2-1


title: MSA207_P02_ESTRIOL 0.03_uM 6_hours 3121-2-1

value: ESTRIOL


title: MSA207_O23_Nimodipine 1.34_uM 6_hours HEPG2

source_name: cancerCells


title: MSA207_P01_ESTRIOL 0.03_uM 6_hours 581-2-1


title: MSA207_O24_Nimodipine 1.34_uM 6_hours 3234-2-4


title: MSA207_O22_MOCLOBEMIDE 10_uM 6_hours 3234-2-4


title: MSA207_P03_DMSO NA 6_hours 581-2-1


title: MSA207_O19_ETIFENIN 1_uM 6_hours HEPG2


title: MSA207_O21_MOCLOBEMIDE 10_uM 6_hours HEPG2


title: MSA207_O14_DMSO NA 6_hours 3234-2-4


title: MSA207_O17_GLIPIZIDE 0_uM 6_hours HEPG2


title: MSA207_O20_ETIFENIN 1_uM 6_hours 3234-2-4


title: MSA207_O04_DMSO NA 6_hours 3234-2-4


title: MSA207_O03_DMSO NA 6_hours HEPG2


title: MSA207_O12_BUFLOMEDIL HYDROCHLORIDE 1_uM 6_hours 3234-2-4


title: MSA207_O05_BUPROPION HYDROCHLORIDE 0.3_uM 6_hours HEPG2


title: MSA207_O06_BUPROPION HYDROCHLORIDE 0.3_uM 6_hours 3234-2-4


title: MSA207_O18_GLIPIZIDE 0_uM 6_hours 3234-2-4


title: MSA207_O10_CETOCYCLINE' 'A-13428' 0.3_uM 6_hours 3234-2-4


title: MSA207_O13_DMSO NA 6_hours HEPG2


title: MSA207_O16_ETHOXZOLAMIDE 0_uM 6_hours 3234-2-4


title: MSA207_O11_BUFLOMEDIL HYDROCHLORIDE 1_uM 6_hours HEPG2


title: MSA207_O07_VATALANIB 1_uM 6_hours HEPG2


title: MSA207_O08_VATALANIB 1_uM 6_hours 3234-2-4


title: MSA207_O09_CETOCYCLINE' 'A-13428' 0.3_uM 6_hours HEPG2


title: MSA207_O15_ETHOXZOLAMIDE 0_uM 6_hours HEPG2


title: MSA207_O01_ESTRIOL 0.03_uM 6_hours HEPG2


title: MSA207_N23_BAY K8644 1.34_uM 6_hours 581-2-1

value: BAY K8644


title: MSA207_O02_ESTRIOL 0.03_uM 6_hours 3234-2-4


title: MSA207_N22_CLOZAPINE 0.1_uM 6_hours 3121-2-1

value: CLOZAPINE


title: MSA207_N20_anisomycin 0.1_uM 6_hours 3121-2-1

value: anisomycin


title: MSA207_N21_CLOZAPINE 0.1_uM 6_hours 581-2-1


title: MSA207_N19_anisomycin 0.1_uM 6_hours 581-2-1


title: MSA207_N24_BAY K8644 1.34_uM 6_hours 3121-2-1


title: MSA207_N18_trichostatin A 0.13_uM 6_hours 3121-2-1

value: trichostatin A

value: poscon


title: MSA207_N16_WB-4101 HYDROCHLORIDE 0_uM 6_hours 3121-2-1

value: WB-4101 HYDROCHLORIDE

value: test


title: PEK1_L4440_1

value: PEK1 knockout

tag: developmental stage

value: young adult

value: pL4440 (Empty vector)


title: MSA207_N13_Aripiprazole 0.03_uM 6_hours 581-2-1

value: Aripiprazole


title: MSA207_M23_BAY K8644 1.34_uM 6_hours HEPG2


title: MSA207_N08_DMSO NA 6_hours 3121-2-1

value: DMSO

value: vehicle


title: MSA207_N03_GT-2394 RAC 10_uM 6_hours 581-2-1

value: GT-2394 RAC


title: MSA207_N06_DL-thiorphan 0.3_uM 6_hours 3121-2-1

value: DL-thiorphan


title: IRE1_L4440_2

value: IRE1 knockout


title: MSA207_N17_trichostatin A 0.13_uM 6_hours 581-2-1


title: MSA207_N14_Aripiprazole 0.03_uM 6_hours 3121-2-1


title: MSA207_N10_ILOPERIDONE 0.01_uM 6_hours 3121-2-1

value: ILOPERIDONE


title: MSA207_N09_ILOPERIDONE 0.01_uM 6_hours 581-2-1


title: MSA207_N04_GT-2394 RAC 10_uM 6_hours 3121-2-1


title: MSA207_M22_CLOZAPINE 0.1_uM 6_hours 3234-2-4


title: MSA207_N01_BOSUTINIB 0.01_uM 6_hours 581-2-1

value: BOSUTINIB


title: MSA207_N05_DL-thiorphan 0.3_uM 6_hours 581-2-1


title: MSA207_M21_CLOZAPINE 0.1_uM 6_hours HEPG2

value: CLOZAPINE


title: MSA207_N12_SORAFENIB 0.03_uM 6_hours 3121-2-1

value: SORAFENIB


title: MSA207_N11_SORAFENIB 0.03_uM 6_hours 581-2-1


title: MSA207_N15_WB-4101 HYDROCHLORIDE 0_uM 6_hours 581-2-1


title: MSA207_M20_anisomycin 0.1_uM 6_hours 3234-2-4

value: anisomycin


title: MSA207_N07_DMSO NA 6_hours 581-2-1


title: MSA207_M24_BAY K8644 1.34_uM 6_hours 3234-2-4

value: BAY K8644


title: MSA207_M17_trichostatin A 0.13_uM 6_hours HEPG2

value: trichostatin A

value: poscon


title: MSA207_M18_trichostatin A 0.13_uM 6_hours 3234-2-4


title: MSA207_M19_anisomycin 0.1_uM 6_hours HEPG2

value: test


title: MSA207_N02_BOSUTINIB 0.01_uM 6_hours 3121-2-1


title: MSA207_M15_WB-4101 HYDROCHLORIDE 0_uM 6_hours HEPG2

value: WB-4101 HYDROCHLORIDE


title: MSA207_M08_DMSO NA 6_hours 3234-2-4


title: MSA207_M14_Aripiprazole 0.03_uM 6_hours 3234-2-4


title: MSA207_M12_SORAFENIB 0.03_uM 6_hours 3234-2-4


title: MSA207_M09_ILOPERIDONE 0.01_uM 6_hours HEPG2


title: MSA207_M11_SORAFENIB 0.03_uM 6_hours HEPG2


title: MSA207_M13_Aripiprazole 0.03_uM 6_hours HEPG2


title: MSA207_M04_GT-2394 RAC 10_uM 6_hours 3234-2-4


title: MSA207_L22_N6-CYCLOPENTYLADENOSINE 1_uM 6_hours 3121-2-1


title: MSA207_M05_DL-thiorphan 0.3_uM 6_hours HEPG2


title: MSA207_M03_GT-2394 RAC 10_uM 6_hours HEPG2


title: MSA207_M01_BOSUTINIB 0.01_uM 6_hours HEPG2


title: MSA207_L20_DMSO NA 6_hours 3121-2-1


title: MSA207_M02_BOSUTINIB 0.01_uM 6_hours 3234-2-4


title: MSA207_L21_N6-CYCLOPENTYLADENOSINE 1_uM 6_hours 581-2-1


title: MSA207_L24_MDL100907 0.67_uM 6_hours 3121-2-1


title: MSA207_L18_celastrol 10_uM 6_hours 3121-2-1

value: celastrol


title: MSA207_L19_DMSO NA 6_hours 581-2-1


title: MSA207_L17_celastrol 10_uM 6_hours 581-2-1


title: MSA207_M07_DMSO NA 6_hours HEPG2


title: MSA207_M10_ILOPERIDONE 0.01_uM 6_hours 3234-2-4


title: MSA207_M06_DL-thiorphan 0.3_uM 6_hours 3234-2-4


title: MSA207_L13_IOFETAMINE HYDROCHLORIDE 10_uM 6_hours 581-2-1

value: IOFETAMINE HYDROCHLORIDE


title: MSA207_L11_norethindrone 0.01_uM 6_hours 581-2-1

value: norethindrone


title: MSA207_L14_IOFETAMINE HYDROCHLORIDE 10_uM 6_hours 3121-2-1


title: MSA207_L23_MDL100907 0.67_uM 6_hours 581-2-1


title: MSA207_L15_GABAZINE 1_uM 6_hours 581-2-1

value: GABAZINE


title: MSA207_L07_METHYLPARABEN 10_uM 6_hours 581-2-1

value: METHYLPARABEN


title: MSA207_L09_SB-242235 0.3_uM 6_hours 581-2-1


title: MSA207_L06_CORTICOSTERONE 0.01_uM 6_hours 3121-2-1

value: CORTICOSTERONE


title: MSA207_L03_tanespimycin NA 6_hours 581-2-1

value: tanespimycin


title: MSA207_L08_METHYLPARABEN 10_uM 6_hours 3121-2-1


title: MSA207_L16_GABAZINE 1_uM 6_hours 3121-2-1


title: MSA207_L12_norethindrone 0.01_uM 6_hours 3121-2-1


title: MSA207_L02_MAFENIDE HYDROCHLORIDE 0_uM 6_hours 3121-2-1

value: MAFENIDE HYDROCHLORIDE


title: MSA207_M16_WB-4101 HYDROCHLORIDE 0_uM 6_hours 3234-2-4


title: MSA207_L10_SB-242235 0.3_uM 6_hours 3121-2-1


title: MSA207_L01_MAFENIDE HYDROCHLORIDE 0_uM 6_hours 581-2-1


title: MSA207_K19_DMSO NA 6_hours HEPG2

value: DMSO

value: vehicle


title: MSA207_K24_MDL100907 0.67_uM 6_hours 3234-2-4


title: MSA207_K20_DMSO NA 6_hours 3234-2-4


title: MSA207_K22_N6-CYCLOPENTYLADENOSINE 1_uM 6_hours 3234-2-4


title: MSA207_L04_tanespimycin NA 6_hours 3121-2-1


title: MSA207_L05_CORTICOSTERONE 0.01_uM 6_hours 581-2-1


title: MSA207_K17_celastrol 10_uM 6_hours HEPG2


title: MSA207_K18_celastrol 10_uM 6_hours 3234-2-4


title: MSA207_K16_GABAZINE 1_uM 6_hours 3234-2-4


title: MSA207_K23_MDL100907 0.67_uM 6_hours HEPG2


title: MSA207_K21_N6-CYCLOPENTYLADENOSINE 1_uM 6_hours HEPG2


title: MSA207_K12_norethindrone 0.01_uM 6_hours 3234-2-4


title: MSA207_K14_IOFETAMINE HYDROCHLORIDE 10_uM 6_hours 3234-2-4


title: MSA207_K15_GABAZINE 1_uM 6_hours HEPG2


title: MSA207_K11_norethindrone 0.01_uM 6_hours HEPG2


title: MSA207_K10_SB-242235 0.3_uM 6_hours 3234-2-4


title: MSA207_K09_SB-242235 0.3_uM 6_hours HEPG2


title: MSA207_K08_METHYLPARABEN 10_uM 6_hours 3234-2-4


title: MSA207_K03_tanespimycin NA 6_hours HEPG2


title: MSA207_K01_MAFENIDE HYDROCHLORIDE 0_uM 6_hours HEPG2


title: MSA207_K05_CORTICOSTERONE 0.01_uM 6_hours HEPG2


title: MSA207_J22_Chlorpromazine 0.03_uM 6_hours 3121-2-1

value: Chlorpromazine


title: MSA207_J21_Chlorpromazine 0.03_uM 6_hours 581-2-1


title: MSA207_K02_MAFENIDE HYDROCHLORIDE 0_uM 6_hours 3234-2-4


title: MSA207_J24_TCB-2 0.13_uM 6_hours 3121-2-1


title: MSA207_K13_IOFETAMINE HYDROCHLORIDE 10_uM 6_hours HEPG2


title: MSA207_J20_DIHYDROSTILBESTROL 0_uM 6_hours 3121-2-1

value: DIHYDROSTILBESTROL


title: MSA207_K04_tanespimycin NA 6_hours 3234-2-4


title: MSA207_K06_CORTICOSTERONE 0.01_uM 6_hours 3234-2-4


title: MSA207_J18_niclosamide 0.03_uM 6_hours 3121-2-1

value: niclosamide


title: MSA207_J19_DIHYDROSTILBESTROL 0_uM 6_hours 581-2-1


title: MSA207_J17_niclosamide 0.03_uM 6_hours 581-2-1


title: MSA207_J13_3-acetamidocoumarin 0.01_uM 6_hours 581-2-1


title: MSA207_J14_3-acetamidocoumarin 0.01_uM 6_hours 3121-2-1


title: MSA207_K07_METHYLPARABEN 10_uM 6_hours HEPG2


title: MSA207_J11_suloctidil 1_uM 6_hours 581-2-1

value: suloctidil


title: MSA207_J16_DMSO NA 6_hours 3121-2-1


title: MSA207_J08_TIAGABINE 1_uM 6_hours 3121-2-1

value: TIAGABINE


title: MSA207_J10_TRANYLCYPROMINE HYDROCHLORIDE 3_uM 6_hours 3121-2-1

value: TRANYLCYPROMINE HYDROCHLORIDE

value: test


title: MSA207_J07_TIAGABINE 1_uM 6_hours 581-2-1


title: MSA207_J12_suloctidil 1_uM 6_hours 3121-2-1


title: MSA207_J23_TCB-2 0.13_uM 6_hours 581-2-1


title: MSA207_J15_DMSO NA 6_hours 581-2-1


title: MSA207_J09_TRANYLCYPROMINE HYDROCHLORIDE 3_uM 6_hours 581-2-1


title: MSA207_J06_nefopam 0.3_uM 6_hours 3121-2-1

value: nefopam


title: MSA207_J05_nefopam 0.3_uM 6_hours 581-2-1


title: MSA207_J04_EPLERENONE 3_uM 6_hours 3121-2-1

value: EPLERENONE


title: MSA207_I20_DIHYDROSTILBESTROL 0_uM 6_hours 3234-2-4


title: MSA207_I22_Chlorpromazine 0.03_uM 6_hours 3234-2-4


title: MSA207_I17_niclosamide 0.03_uM 6_hours HEPG2


title: MSA207_J01_DMSO NA 6_hours 581-2-1


title: MSA207_I19_DIHYDROSTILBESTROL 0_uM 6_hours HEPG2


title: MSA207_I15_DMSO NA 6_hours HEPG2


title: MSA207_I24_TCB-2 0.13_uM 6_hours 3234-2-4


title: MSA207_I12_suloctidil 1_uM 6_hours 3234-2-4


title: MSA207_J02_DMSO NA 6_hours 3121-2-1


title: MSA207_I16_DMSO NA 6_hours 3234-2-4


title: MSA207_J03_EPLERENONE 3_uM 6_hours 581-2-1


title: MSA207_I11_suloctidil 1_uM 6_hours HEPG2


title: MSA207_I23_TCB-2 0.13_uM 6_hours HEPG2


title: MSA207_I05_nefopam 0.3_uM 6_hours HEPG2


title: MSA207_I21_Chlorpromazine 0.03_uM 6_hours HEPG2


title: MSA207_I03_EPLERENONE 3_uM 6_hours HEPG2


title: MSA207_I06_nefopam 0.3_uM 6_hours 3234-2-4


title: MSA207_I09_TRANYLCYPROMINE HYDROCHLORIDE 3_uM 6_hours HEPG2


title: MSA207_I08_TIAGABINE 1_uM 6_hours 3234-2-4


title: MSA207_I02_DMSO NA 6_hours 3234-2-4


title: MSA207_I14_3-acetamidocoumarin 0.01_uM 6_hours 3234-2-4


title: MSA207_I01_DMSO NA 6_hours HEPG2


title: MSA207_I04_EPLERENONE 3_uM 6_hours 3234-2-4


title: MSA207_I13_3-acetamidocoumarin 0.01_uM 6_hours HEPG2


title: MSA207_H24_DMSO NA 6_hours 3121-2-1


title: MSA207_I07_TIAGABINE 1_uM 6_hours HEPG2


title: MSA207_H19_ESTRONE 0.03_uM 6_hours 581-2-1

value: ESTRONE


title: MSA207_I10_TRANYLCYPROMINE HYDROCHLORIDE 3_uM 6_hours 3234-2-4


title: MSA207_I18_niclosamide 0.03_uM 6_hours 3234-2-4


title: MSA207_H22_chenodeoxycholic acid 10_uM 6_hours 3121-2-1

value: chenodeoxycholic acid


title: MSA207_H12_CONESSINE 0.3_uM 6_hours 3121-2-1

value: CONESSINE


title: MSA207_H17_GLAXO:GR247538 1_uM 6_hours 581-2-1


title: MSA207_H15_MEMANTINE HYDROCHLORIDE 0.01_uM 6_hours 581-2-1

value: MEMANTINE HYDROCHLORIDE


title: MSA207_H20_ESTRONE 0.03_uM 6_hours 3121-2-1


title: MSA207_H13_BMS-250904 0.3_uM 6_hours 581-2-1


title: MSA207_H23_DMSO NA 6_hours 581-2-1


title: MSA207_H21_chenodeoxycholic acid 10_uM 6_hours 581-2-1


title: MSA207_H14_BMS-250904 0.3_uM 6_hours 3121-2-1


title: MSA207_H08_KANPAULLONE 0.1_uM 6_hours 3121-2-1

value: KANPAULLONE


title: MSA207_H03_Quetiapine 0.3_uM 6_hours 581-2-1

value: Quetiapine


title: MSA207_H16_MEMANTINE HYDROCHLORIDE 0.01_uM 6_hours 3121-2-1


title: MSA207_H01_CM ZA 0576 1_uM 6_hours 581-2-1

value: CM ZA 0576


title: MSA207_H05_HARMINE HYDROCHLORIDE 0.3_uM 6_hours 581-2-1

value: HARMINE HYDROCHLORIDE


title: MSA207_H04_Quetiapine 0.3_uM 6_hours 3121-2-1


title: MSA207_H11_CONESSINE 0.3_uM 6_hours 581-2-1


title: MSA207_H10_trichostatin A 0.13_uM 6_hours 3121-2-1

value: trichostatin A

value: poscon


title: MSA207_H09_trichostatin A 0.13_uM 6_hours 581-2-1


title: MSA207_H07_KANPAULLONE 0.1_uM 6_hours 581-2-1


title: MSA207_H06_HARMINE HYDROCHLORIDE 0.3_uM 6_hours 3121-2-1


title: MSA207_G22_chenodeoxycholic acid 10_uM 6_hours 3234-2-4


title: MSA207_H18_GLAXO:GR247538 1_uM 6_hours 3121-2-1


title: MSA207_G24_DMSO NA 6_hours 3234-2-4

value: DMSO

value: vehicle


title: MSA207_G23_DMSO NA 6_hours HEPG2


title: MSA207_G20_ESTRONE 0.03_uM 6_hours 3234-2-4


title: MSA207_H02_CM ZA 0576 1_uM 6_hours 3121-2-1


title: MSA207_G21_chenodeoxycholic acid 10_uM 6_hours HEPG2


title: MSA207_G18_GLAXO:GR247538 1_uM 6_hours 3234-2-4


title: MSA207_G19_ESTRONE 0.03_uM 6_hours HEPG2


title: MSA207_G15_MEMANTINE HYDROCHLORIDE 0.01_uM 6_hours HEPG2


title: MSA207_G17_GLAXO:GR247538 1_uM 6_hours HEPG2


title: MSA207_G13_BMS-250904 0.3_uM 6_hours HEPG2


title: MSA207_G12_CONESSINE 0.3_uM 6_hours 3234-2-4


title: MSA207_G16_MEMANTINE HYDROCHLORIDE 0.01_uM 6_hours 3234-2-4


title: MSA207_G14_BMS-250904 0.3_uM 6_hours 3234-2-4


title: MSA207_G09_trichostatin A 0.13_uM 6_hours HEPG2


title: MSA207_G11_CONESSINE 0.3_uM 6_hours HEPG2


title: MSA207_G10_trichostatin A 0.13_uM 6_hours 3234-2-4


title: MSA207_G02_CM ZA 0576 1_uM 6_hours 3234-2-4


title: MSA207_G06_HARMINE HYDROCHLORIDE 0.3_uM 6_hours 3234-2-4


title: MSA207_F23_LY379268 0.13_uM 6_hours 581-2-1


title: MSA207_F18_DMSO NA 6_hours 3121-2-1


title: MSA207_G07_KANPAULLONE 0.1_uM 6_hours HEPG2


title: MSA207_F24_LY379268 0.13_uM 6_hours 3121-2-1


title: MSA207_G01_CM ZA 0576 1_uM 6_hours HEPG2


title: MSA207_G08_KANPAULLONE 0.1_uM 6_hours 3234-2-4


title: MSA207_F21_NALOXONE HYDROCHLORIDE 0_uM 6_hours 581-2-1

value: NALOXONE HYDROCHLORIDE


title: MSA207_F17_DMSO NA 6_hours 581-2-1


title: MSA207_F19_EQUILENIN 0.03_uM 6_hours 581-2-1

value: EQUILENIN


title: MSA207_G04_Quetiapine 0.3_uM 6_hours 3234-2-4

value: test


title: MSA207_F16_NOGESTREL 0.01_uM 6_hours 3121-2-1

value: NOGESTREL


title: MSA207_F13_salsolidin 10_uM 6_hours 581-2-1

value: salsolidin


title: MSA207_G03_Quetiapine 0.3_uM 6_hours HEPG2


title: MSA207_F20_EQUILENIN 0.03_uM 6_hours 3121-2-1


title: MSA207_F15_NOGESTREL 0.01_uM 6_hours 581-2-1


title: MSA207_F12_DMSO NA 6_hours 3121-2-1


title: MSA207_F14_salsolidin 10_uM 6_hours 3121-2-1


title: MSA207_F09_VANDETANIB 0.3_uM 6_hours 581-2-1

value: VANDETANIB


title: MSA207_F10_VANDETANIB 0.3_uM 6_hours 3121-2-1


title: MSA207_F08_URAPIDIL, 5-METHYL- 0.1_uM 6_hours 3121-2-1

value: URAPIDIL, 5-METHYL-


title: MSA207_F06_LAMIVUDINE 3_uM 6_hours 3121-2-1

value: LAMIVUDINE


title: MSA207_F07_URAPIDIL, 5-METHYL- 0.1_uM 6_hours 581-2-1


title: MSA207_F05_LAMIVUDINE 3_uM 6_hours 581-2-1


title: MSA207_F04_MDL 29951 3_uM 6_hours 3121-2-1


title: MSA207_F02_diltiazem 0.3_uM 6_hours 3121-2-1

value: diltiazem


title: MSA207_F03_MDL 29951 3_uM 6_hours 581-2-1


title: MSA207_E23_LY379268 0.13_uM 6_hours HEPG2


title: MSA207_E21_NALOXONE HYDROCHLORIDE 0_uM 6_hours HEPG2


title: MSA207_E20_EQUILENIN 0.03_uM 6_hours 3234-2-4


title: MSA207_E24_LY379268 0.13_uM 6_hours 3234-2-4


title: MSA207_F01_diltiazem 0.3_uM 6_hours 581-2-1


title: MSA207_E16_NOGESTREL 0.01_uM 6_hours 3234-2-4


title: MSA207_E22_NALOXONE HYDROCHLORIDE 0_uM 6_hours 3234-2-4


title: MSA207_G05_HARMINE HYDROCHLORIDE 0.3_uM 6_hours HEPG2


title: MSA207_E14_salsolidin 10_uM 6_hours 3234-2-4


title: MSA207_E13_salsolidin 10_uM 6_hours HEPG2


title: MSA207_E17_DMSO NA 6_hours HEPG2


title: MSA207_E15_NOGESTREL 0.01_uM 6_hours HEPG2


title: MSA207_E18_DMSO NA 6_hours 3234-2-4


title: MSA207_E19_EQUILENIN 0.03_uM 6_hours HEPG2


title: MSA207_E12_DMSO NA 6_hours 3234-2-4


title: MSA207_E11_DMSO NA 6_hours HEPG2


title: MSA207_E07_URAPIDIL, 5-METHYL- 0.1_uM 6_hours HEPG2


title: MSA207_E10_VANDETANIB 0.3_uM 6_hours 3234-2-4


title: MSA207_E03_MDL 29951 3_uM 6_hours HEPG2


title: MSA207_E08_URAPIDIL, 5-METHYL- 0.1_uM 6_hours 3234-2-4


title: MSA207_E06_LAMIVUDINE 3_uM 6_hours 3234-2-4


title: MSA207_E05_LAMIVUDINE 3_uM 6_hours HEPG2


title: MSA207_E02_diltiazem 0.3_uM 6_hours 3234-2-4


title: MSA207_E04_MDL 29951 3_uM 6_hours 3234-2-4


title: MSA207_F11_DMSO NA 6_hours 581-2-1


title: MSA207_D24_quinpirole 0.13_uM 6_hours 3121-2-1

value: quinpirole


title: MSA207_E01_diltiazem 0.3_uM 6_hours HEPG2


title: MSA207_D22_SB 43152 1_uM 6_hours 3121-2-1


title: MSA207_D21_SB 43152 1_uM 6_hours 581-2-1


title: MSA207_D23_quinpirole 0.13_uM 6_hours 581-2-1


title: MSA207_D20_BENZYLOXYCARBONYL-L-GLYCYL-L-PHENYLALANYL-L-PHENYLALANYL-L-TYROSINEBENZYL ESTER 1_uM 6_hours 3121-2-1


title: MSA207_D19_BENZYLOXYCARBONYL-L-GLYCYL-L-PHENYLALANYL-L-PHENYLALANYL-L-TYROSINEBENZYL ESTER 1_uM 6_hours 581-2-1


title: MSA207_E09_VANDETANIB 0.3_uM 6_hours HEPG2


title: MSA207_D16_mebendazole 0.3_uM 6_hours 3121-2-1

value: mebendazole


title: MSA207_D18_Ziprasidone 0.03_uM 6_hours 3121-2-1

value: Ziprasidone


title: MSA207_D10_DMSO NA 6_hours 3121-2-1


title: MSA207_D17_Ziprasidone 0.03_uM 6_hours 581-2-1


title: MSA207_D07_phenelzine 0_uM 6_hours 581-2-1

value: phenelzine


title: MSA207_D08_phenelzine 0_uM 6_hours 3121-2-1


title: MSA207_D12_DIPHENYLAMINOTRIAZINE 3_uM 6_hours 3121-2-1

value: DIPHENYLAMINOTRIAZINE


title: MSA207_D14_tanespimycin NA 6_hours 3121-2-1

value: tanespimycin

value: poscon


title: MSA207_D06_DMSO NA 6_hours 3121-2-1

value: DMSO

value: vehicle


title: MSA207_C20_BENZYLOXYCARBONYL-L-GLYCYL-L-PHENYLALANYL-L-PHENYLALANYL-L-TYROSINEBENZYL ESTER 1_uM 6_hours 3234-2-4


title: MSA207_C24_quinpirole 0.13_uM 6_hours 3234-2-4


title: MSA207_C22_SB 43152 1_uM 6_hours 3234-2-4


title: MSA207_D04_DORZOLAMIDE HYDROCHLORIDE 0.1_uM 6_hours 3121-2-1

value: DORZOLAMIDE HYDROCHLORIDE


title: MSA207_D13_tanespimycin NA 6_hours 581-2-1


title: MSA207_D03_DORZOLAMIDE HYDROCHLORIDE 0.1_uM 6_hours 581-2-1

value: test


title: MSA207_D09_DMSO NA 6_hours 581-2-1


title: MSA207_D11_DIPHENYLAMINOTRIAZINE 3_uM 6_hours 581-2-1


title: MSA207_C21_SB 43152 1_uM 6_hours HEPG2


title: MSA207_D15_mebendazole 0.3_uM 6_hours 581-2-1


title: MSA207_C23_quinpirole 0.13_uM 6_hours HEPG2


title: MSA207_C18_Ziprasidone 0.03_uM 6_hours 3234-2-4


title: MSA207_C15_mebendazole 0.3_uM 6_hours HEPG2


title: MSA207_C19_BENZYLOXYCARBONYL-L-GLYCYL-L-PHENYLALANYL-L-PHENYLALANYL-L-TYROSINEBENZYL ESTER 1_uM 6_hours HEPG2


title: MSA207_F22_NALOXONE HYDROCHLORIDE 0_uM 6_hours 3121-2-1

value: NALOXONE HYDROCHLORIDE


title: MSA207_C17_Ziprasidone 0.03_uM 6_hours HEPG2


title: MSA207_C13_tanespimycin NA 6_hours HEPG2


title: MSA207_C14_tanespimycin NA 6_hours 3234-2-4


title: MSA207_C10_DMSO NA 6_hours 3234-2-4


title: MSA207_C12_DIPHENYLAMINOTRIAZINE 3_uM 6_hours 3234-2-4


title: MSA207_C09_DMSO NA 6_hours HEPG2


title: MSA207_C05_DMSO NA 6_hours HEPG2


title: MSA207_C11_DIPHENYLAMINOTRIAZINE 3_uM 6_hours HEPG2


title: MSA207_C08_phenelzine 0_uM 6_hours 3234-2-4


title: MSA207_C07_phenelzine 0_uM 6_hours HEPG2


title: MSA207_C02_PERCEPTIN 0.3_uM 6_hours 3234-2-4

value: PERCEPTIN


title: MSA207_C03_DORZOLAMIDE HYDROCHLORIDE 0.1_uM 6_hours HEPG2


title: MSA207_C01_PERCEPTIN 0.3_uM 6_hours HEPG2


title: MSA207_C04_DORZOLAMIDE HYDROCHLORIDE 0.1_uM 6_hours 3234-2-4


title: MSA207_B23_PODOPHYLLOTOXIN 0.01_uM 6_hours 581-2-1

value: PODOPHYLLOTOXIN


title: MSA207_B22_DMSO NA 6_hours 3121-2-1


title: MSA207_B21_DMSO NA 6_hours 581-2-1


title: MSA207_B24_PODOPHYLLOTOXIN 0.01_uM 6_hours 3121-2-1


title: MSA207_B20_POTASSIUM ESTRONE SULFATE 0.03_uM 6_hours 3121-2-1

value: POTASSIUM ESTRONE SULFATE


title: MSA207_C06_DMSO NA 6_hours 3234-2-4


title: MSA207_B19_POTASSIUM ESTRONE SULFATE 0.03_uM 6_hours 581-2-1


title: MSA207_B18_NALTREXONE HYDROCHLORIDE 0_uM 6_hours 3121-2-1

value: NALTREXONE HYDROCHLORIDE


title: MSA207_B17_NALTREXONE HYDROCHLORIDE 0_uM 6_hours 581-2-1


title: MSA207_B15_RISPERIDONE 0.03_uM 6_hours 581-2-1

value: RISPERIDONE


title: MSA207_B16_RISPERIDONE 0.03_uM 6_hours 3121-2-1


title: MSA207_B14_SPIRONOLACTONE 0.1_uM 6_hours 3121-2-1

value: SPIRONOLACTONE


title: MSA207_B13_SPIRONOLACTONE 0.1_uM 6_hours 581-2-1


title: MSA207_B07_ANDROSTERONE 0.03_uM 6_hours 581-2-1

value: ANDROSTERONE


title: MSA207_B06_QUIPAZINE, N-METHYL-, DIMALEATE 0.03_uM 6_hours 3121-2-1

value: QUIPAZINE, N-METHYL-, DIMALEATE


title: MSA207_B12_UNC0638 0.1_uM 6_hours 3121-2-1


title: MSA207_B11_UNC0638 0.1_uM 6_hours 581-2-1


title: MSA207_B04_NORFLOXACIN 10_uM 6_hours 3121-2-1

value: NORFLOXACIN


title: MSA207_B05_QUIPAZINE, N-METHYL-, DIMALEATE 0.03_uM 6_hours 581-2-1


title: MSA207_A23_PODOPHYLLOTOXIN 0.01_uM 6_hours HEPG2


title: MSA207_B03_NORFLOXACIN 10_uM 6_hours 581-2-1


title: MSA207_A22_DMSO NA 6_hours 3234-2-4


title: MSA207_B09_lycorine 3_uM 6_hours 581-2-1

value: lycorine


title: MSA207_A24_PODOPHYLLOTOXIN 0.01_uM 6_hours 3234-2-4


title: MSA207_A18_NALTREXONE HYDROCHLORIDE 0_uM 6_hours 3234-2-4


title: MSA207_A20_POTASSIUM ESTRONE SULFATE 0.03_uM 6_hours 3234-2-4


title: MSA207_A17_NALTREXONE HYDROCHLORIDE 0_uM 6_hours HEPG2


title: MSA207_B10_lycorine 3_uM 6_hours 3121-2-1


title: MSA207_A19_POTASSIUM ESTRONE SULFATE 0.03_uM 6_hours HEPG2


title: MSA207_A16_RISPERIDONE 0.03_uM 6_hours 3234-2-4


title: MSA207_A15_RISPERIDONE 0.03_uM 6_hours HEPG2


title: MSA207_B08_ANDROSTERONE 0.03_uM 6_hours 3121-2-1


title: MSA207_A13_SPIRONOLACTONE 0.1_uM 6_hours HEPG2


title: MSA207_A21_DMSO NA 6_hours HEPG2


title: MSA207_A14_SPIRONOLACTONE 0.1_uM 6_hours 3234-2-4


title: MSA207_A12_UNC0638 0.1_uM 6_hours 3234-2-4


title: MSA207_A11_UNC0638 0.1_uM 6_hours HEPG2


title: MSA206_P23_Nimodipine 1.34_uM 6_hours 2484-2-A

value: Nimodipine


title: MSA207_A08_ANDROSTERONE 0.03_uM 6_hours 3234-2-4


title: MSA206_P21_MOCLOBEMIDE 10_uM 6_hours 2484-2-A

value: MOCLOBEMIDE


title: MSA206_P22_MOCLOBEMIDE 10_uM 6_hours 449-2-12


title: MSA207_A06_QUIPAZINE, N-METHYL-, DIMALEATE 0.03_uM 6_hours 3234-2-4


title: MSA207_A04_NORFLOXACIN 10_uM 6_hours 3234-2-4


title: MSA206_P19_ETIFENIN 1_uM 6_hours 2484-2-A

value: ETIFENIN


title: MSA207_A07_ANDROSTERONE 0.03_uM 6_hours HEPG2


title: MSA206_P24_Nimodipine 1.34_uM 6_hours 449-2-12


title: MSA207_A10_lycorine 3_uM 6_hours 3234-2-4


title: MSA207_A05_QUIPAZINE, N-METHYL-, DIMALEATE 0.03_uM 6_hours HEPG2


title: MSA206_P18_GLIPIZIDE 0_uM 6_hours 449-2-12

value: GLIPIZIDE


title: MSA206_P12_BUFLOMEDIL HYDROCHLORIDE 1_uM 6_hours 449-2-12

value: BUFLOMEDIL HYDROCHLORIDE


title: MSA206_P20_ETIFENIN 1_uM 6_hours 449-2-12

value: test


title: MSA206_P17_GLIPIZIDE 0_uM 6_hours 2484-2-A


title: MSA207_A03_NORFLOXACIN 10_uM 6_hours HEPG2


title: MSA206_P16_ETHOXZOLAMIDE 0_uM 6_hours 449-2-12

value: ETHOXZOLAMIDE


title: MSA206_P10_CETOCYCLINE' 'A-13428' 0.3_uM 6_hours 449-2-12

value: CETOCYCLINE' 'A-13428'


title: MSA206_P11_BUFLOMEDIL HYDROCHLORIDE 1_uM 6_hours 2484-2-A


title: MSA206_P15_ETHOXZOLAMIDE 0_uM 6_hours 2484-2-A


title: MSA206_P09_CETOCYCLINE' 'A-13428' 0.3_uM 6_hours 2484-2-A


title: MSA207_A09_lycorine 3_uM 6_hours HEPG2


title: MSA207_D01_PERCEPTIN 0.3_uM 6_hours 581-2-1

value: PERCEPTIN


title: MSA206_P13_DMSO NA 6_hours 2484-2-A

value: DMSO

value: vehicle


title: MSA207_D05_DMSO NA 6_hours 581-2-1


title: MSA206_P14_DMSO NA 6_hours 449-2-12


title: MSA206_P05_BUPROPION HYDROCHLORIDE 0.3_uM 6_hours 2484-2-A

value: BUPROPION HYDROCHLORIDE


title: MSA206_P04_DMSO NA 6_hours 449-2-12


title: MSA206_O24_Nimodipine 1.34_uM 6_hours 3182-2-4


title: MSA206_P01_ESTRIOL 0.03_uM 6_hours 2484-2-A

value: ESTRIOL


title: MSA206_P06_BUPROPION HYDROCHLORIDE 0.3_uM 6_hours 449-2-12


title: MSA206_P03_DMSO NA 6_hours 2484-2-A


title: MSA206_P08_VATALANIB 1_uM 6_hours 449-2-12

value: VATALANIB


title: MSA206_O23_Nimodipine 1.34_uM 6_hours VCAP

value: VCAP


title: MSA206_O22_MOCLOBEMIDE 10_uM 6_hours 3182-2-4


title: MSA207_C16_mebendazole 0.3_uM 6_hours 3234-2-4

value: mebendazole


title: MSA206_O20_ETIFENIN 1_uM 6_hours 3182-2-4


title: MSA206_O18_GLIPIZIDE 0_uM 6_hours 3182-2-4


title: MSA206_O21_MOCLOBEMIDE 10_uM 6_hours VCAP


title: MSA206_O19_ETIFENIN 1_uM 6_hours VCAP


title: MSA206_O13_DMSO NA 6_hours VCAP


title: MSA206_O12_BUFLOMEDIL HYDROCHLORIDE 1_uM 6_hours 3182-2-4


title: MSA206_O15_ETHOXZOLAMIDE 0_uM 6_hours VCAP


title: MSA206_O17_GLIPIZIDE 0_uM 6_hours VCAP


title: MSA206_P02_ESTRIOL 0.03_uM 6_hours 449-2-12


title: MSA206_O08_VATALANIB 1_uM 6_hours 3182-2-4


title: MSA206_O11_BUFLOMEDIL HYDROCHLORIDE 1_uM 6_hours VCAP


title: MSA206_O14_DMSO NA 6_hours 3182-2-4


title: MSA206_O10_CETOCYCLINE' 'A-13428' 0.3_uM 6_hours 3182-2-4


title: MSA206_O06_BUPROPION HYDROCHLORIDE 0.3_uM 6_hours 3182-2-4


title: MSA206_O16_ETHOXZOLAMIDE 0_uM 6_hours 3182-2-4


title: MSA206_O07_VATALANIB 1_uM 6_hours VCAP


title: MSA206_O02_ESTRIOL 0.03_uM 6_hours 3182-2-4


title: MSA206_N23_BAY K8644 1.34_uM 6_hours 2484-2-A

value: BAY K8644


title: MSA206_N19_anisomycin 0.1_uM 6_hours 2484-2-A

value: anisomycin


title: MSA206_O04_DMSO NA 6_hours 3182-2-4


title: MSA206_N20_anisomycin 0.1_uM 6_hours 449-2-12


title: MSA206_O09_CETOCYCLINE' 'A-13428' 0.3_uM 6_hours VCAP


title: MSA206_N18_trichostatin A 0.13_uM 6_hours 449-2-12

value: trichostatin A

value: poscon


title: MSA207_D02_PERCEPTIN 0.3_uM 6_hours 3121-2-1


title: MSA206_O05_BUPROPION HYDROCHLORIDE 0.3_uM 6_hours VCAP


title: MSA206_N13_Aripiprazole 0.03_uM 6_hours 2484-2-A

value: Aripiprazole


title: MSA206_N14_Aripiprazole 0.03_uM 6_hours 449-2-12


title: MSA206_N12_SORAFENIB 0.03_uM 6_hours 449-2-12

value: SORAFENIB


title: MSA206_N24_BAY K8644 1.34_uM 6_hours 449-2-12

value: test


title: MSA206_N08_DMSO NA 6_hours 449-2-12


title: MSA206_N11_SORAFENIB 0.03_uM 6_hours 2484-2-A


title: MSA206_N22_CLOZAPINE 0.1_uM 6_hours 449-2-12

value: CLOZAPINE


title: MSA206_N09_ILOPERIDONE 0.01_uM 6_hours 2484-2-A

value: ILOPERIDONE


title: MSA206_N15_WB-4101 HYDROCHLORIDE 0_uM 6_hours 2484-2-A

value: WB-4101 HYDROCHLORIDE


title: MSA206_N07_DMSO NA 6_hours 2484-2-A

value: DMSO


title: MSA206_N16_WB-4101 HYDROCHLORIDE 0_uM 6_hours 449-2-12


title: MSA206_N21_CLOZAPINE 0.1_uM 6_hours 2484-2-A


title: MSA206_N17_trichostatin A 0.13_uM 6_hours 2484-2-A


title: MSA206_N05_DL-thiorphan 0.3_uM 6_hours 2484-2-A

value: DL-thiorphan


title: MSA206_O01_ESTRIOL 0.03_uM 6_hours VCAP


title: MSA206_N04_GT-2394 RAC 10_uM 6_hours 449-2-12

value: GT-2394 RAC


title: MSA206_N06_DL-thiorphan 0.3_uM 6_hours 449-2-12


title: MSA206_N03_GT-2394 RAC 10_uM 6_hours 2484-2-A


title: MSA206_P07_VATALANIB 1_uM 6_hours 2484-2-A


title: MSA206_M24_BAY K8644 1.34_uM 6_hours 3182-2-4


title: MSA206_N01_BOSUTINIB 0.01_uM 6_hours 2484-2-A

value: BOSUTINIB


title: MSA206_N02_BOSUTINIB 0.01_uM 6_hours 449-2-12


title: MSA206_N10_ILOPERIDONE 0.01_uM 6_hours 449-2-12


title: MSA206_M22_CLOZAPINE 0.1_uM 6_hours 3182-2-4


title: MSA206_O03_DMSO NA 6_hours VCAP

value: vehicle


title: MSA206_M21_CLOZAPINE 0.1_uM 6_hours VCAP

value: VCAP


title: MSA206_M19_anisomycin 0.1_uM 6_hours VCAP


title: MSA206_M20_anisomycin 0.1_uM 6_hours 3182-2-4


title: MSA206_M13_Aripiprazole 0.03_uM 6_hours VCAP


title: MSA206_M15_WB-4101 HYDROCHLORIDE 0_uM 6_hours VCAP


title: MSA206_M23_BAY K8644 1.34_uM 6_hours VCAP


title: MSA206_M10_ILOPERIDONE 0.01_uM 6_hours 3182-2-4


title: MSA206_M17_trichostatin A 0.13_uM 6_hours VCAP


title: MSA206_M14_Aripiprazole 0.03_uM 6_hours 3182-2-4


title: MSA206_M12_SORAFENIB 0.03_uM 6_hours 3182-2-4


title: MSA206_M06_DL-thiorphan 0.3_uM 6_hours 3182-2-4


title: MSA206_M09_ILOPERIDONE 0.01_uM 6_hours VCAP


title: MSA206_L22_N6-CYCLOPENTYLADENOSINE 1_uM 6_hours 449-2-12


title: MSA206_M05_DL-thiorphan 0.3_uM 6_hours VCAP


title: MSA206_M01_BOSUTINIB 0.01_uM 6_hours VCAP


title: MSA206_M07_DMSO NA 6_hours VCAP


title: MSA206_M03_GT-2394 RAC 10_uM 6_hours VCAP


title: MSA206_L15_GABAZINE 1_uM 6_hours 2484-2-A

value: GABAZINE


title: MSA206_M04_GT-2394 RAC 10_uM 6_hours 3182-2-4


title: MSA206_L18_celastrol 10_uM 6_hours 449-2-12

value: celastrol


title: MSA206_L20_DMSO NA 6_hours 449-2-12


title: MSA206_M02_BOSUTINIB 0.01_uM 6_hours 3182-2-4


title: MSA206_L21_N6-CYCLOPENTYLADENOSINE 1_uM 6_hours 2484-2-A


title: MSA206_L19_DMSO NA 6_hours 2484-2-A


title: MSA206_L13_IOFETAMINE HYDROCHLORIDE 10_uM 6_hours 2484-2-A

value: IOFETAMINE HYDROCHLORIDE


title: MSA206_L23_MDL100907 0.67_uM 6_hours 2484-2-A


title: MSA206_M18_trichostatin A 0.13_uM 6_hours 3182-2-4

value: trichostatin A


title: MSA206_L16_GABAZINE 1_uM 6_hours 449-2-12


title: MSA206_L12_norethindrone 0.01_uM 6_hours 449-2-12

value: norethindrone


title: MSA206_L14_IOFETAMINE HYDROCHLORIDE 10_uM 6_hours 449-2-12


title: MSA206_L24_MDL100907 0.67_uM 6_hours 449-2-12


title: MSA206_M11_SORAFENIB 0.03_uM 6_hours VCAP


title: MSA206_L17_celastrol 10_uM 6_hours 2484-2-A


title: MSA206_M16_WB-4101 HYDROCHLORIDE 0_uM 6_hours 3182-2-4


title: MSA206_L11_norethindrone 0.01_uM 6_hours 2484-2-A


title: MSA206_L06_CORTICOSTERONE 0.01_uM 6_hours 449-2-12

value: CORTICOSTERONE


title: MSA206_K23_MDL100907 0.67_uM 6_hours VCAP


title: MSA206_K15_GABAZINE 1_uM 6_hours VCAP


title: MSA206_L08_METHYLPARABEN 10_uM 6_hours 449-2-12

value: METHYLPARABEN


title: MSA206_L04_tanespimycin NA 6_hours 449-2-12

value: tanespimycin

value: poscon


title: MSA206_L10_SB-242235 0.3_uM 6_hours 449-2-12

value: test


title: MSA206_L07_METHYLPARABEN 10_uM 6_hours 2484-2-A


title: MSA206_K22_N6-CYCLOPENTYLADENOSINE 1_uM 6_hours 3182-2-4


title: MSA206_L01_MAFENIDE HYDROCHLORIDE 0_uM 6_hours 2484-2-A

value: MAFENIDE HYDROCHLORIDE


title: MSA206_L02_MAFENIDE HYDROCHLORIDE 0_uM 6_hours 449-2-12


title: MSA206_K14_IOFETAMINE HYDROCHLORIDE 10_uM 6_hours 3182-2-4


title: MSA206_L09_SB-242235 0.3_uM 6_hours 2484-2-A


title: MSA206_L05_CORTICOSTERONE 0.01_uM 6_hours 2484-2-A


title: MSA206_K21_N6-CYCLOPENTYLADENOSINE 1_uM 6_hours VCAP


title: MSA206_K19_DMSO NA 6_hours VCAP

value: DMSO


title: MSA206_K17_celastrol 10_uM 6_hours VCAP


title: MSA206_K18_celastrol 10_uM 6_hours 3182-2-4


title: MSA206_K16_GABAZINE 1_uM 6_hours 3182-2-4


title: MSA206_K24_MDL100907 0.67_uM 6_hours 3182-2-4


title: MSA206_L03_tanespimycin NA 6_hours 2484-2-A


title: MSA206_K10_SB-242235 0.3_uM 6_hours 3182-2-4


title: MSA206_K12_norethindrone 0.01_uM 6_hours 3182-2-4


title: MSA206_K09_SB-242235 0.3_uM 6_hours VCAP


title: MSA206_K08_METHYLPARABEN 10_uM 6_hours 3182-2-4


title: MSA206_K20_DMSO NA 6_hours 3182-2-4


title: MSA206_K13_IOFETAMINE HYDROCHLORIDE 10_uM 6_hours VCAP


title: MSA206_K11_norethindrone 0.01_uM 6_hours VCAP


title: MSA206_K07_METHYLPARABEN 10_uM 6_hours VCAP


title: MSA206_K06_CORTICOSTERONE 0.01_uM 6_hours 3182-2-4


title: MSA206_K03_tanespimycin NA 6_hours VCAP


title: MSA206_K04_tanespimycin NA 6_hours 3182-2-4


title: MSA206_K05_CORTICOSTERONE 0.01_uM 6_hours VCAP


title: MSA206_K02_MAFENIDE HYDROCHLORIDE 0_uM 6_hours 3182-2-4


title: MSA206_J24_TCB-2 0.13_uM 6_hours 449-2-12


title: MSA206_J23_TCB-2 0.13_uM 6_hours 2484-2-A


title: MSA206_K01_MAFENIDE HYDROCHLORIDE 0_uM 6_hours VCAP


title: MSA206_J22_Chlorpromazine 0.03_uM 6_hours 449-2-12

value: Chlorpromazine


title: MSA206_J20_DIHYDROSTILBESTROL 0_uM 6_hours 449-2-12

value: DIHYDROSTILBESTROL


title: MSA206_J21_Chlorpromazine 0.03_uM 6_hours 2484-2-A


title: MSA206_J16_DMSO NA 6_hours 449-2-12


title: MSA206_J17_niclosamide 0.03_uM 6_hours 2484-2-A

value: niclosamide


title: MSA206_J15_DMSO NA 6_hours 2484-2-A

value: vehicle


title: MSA206_J14_3-acetamidocoumarin 0.01_uM 6_hours 449-2-12


title: MSA206_J12_suloctidil 1_uM 6_hours 449-2-12

value: suloctidil


title: MSA206_J10_TRANYLCYPROMINE HYDROCHLORIDE 3_uM 6_hours 449-2-12

value: TRANYLCYPROMINE HYDROCHLORIDE


title: MSA206_J19_DIHYDROSTILBESTROL 0_uM 6_hours 2484-2-A


title: MSA206_J13_3-acetamidocoumarin 0.01_uM 6_hours 2484-2-A


title: MSA206_J07_TIAGABINE 1_uM 6_hours 2484-2-A

value: TIAGABINE


title: MSA206_J18_niclosamide 0.03_uM 6_hours 449-2-12


title: MSA206_J08_TIAGABINE 1_uM 6_hours 449-2-12


title: MSA206_J09_TRANYLCYPROMINE HYDROCHLORIDE 3_uM 6_hours 2484-2-A


title: MSA206_J06_nefopam 0.3_uM 6_hours 449-2-12

value: nefopam


title: MSA206_J11_suloctidil 1_uM 6_hours 2484-2-A


title: MSA206_J04_EPLERENONE 3_uM 6_hours 449-2-12

value: EPLERENONE


title: MSA206_J05_nefopam 0.3_uM 6_hours 2484-2-A


title: MSA206_M08_DMSO NA 6_hours 3182-2-4


title: MSA206_J03_EPLERENONE 3_uM 6_hours 2484-2-A


title: MSA206_J01_DMSO NA 6_hours 2484-2-A


title: MSA206_J02_DMSO NA 6_hours 449-2-12


title: MSA206_I24_TCB-2 0.13_uM 6_hours 3182-2-4


title: MSA206_I19_DIHYDROSTILBESTROL 0_uM 6_hours VCAP

value: VCAP


title: MSA206_I23_TCB-2 0.13_uM 6_hours VCAP


title: MSA206_I21_Chlorpromazine 0.03_uM 6_hours VCAP


title: MSA206_I18_niclosamide 0.03_uM 6_hours 3182-2-4


title: MSA206_I15_DMSO NA 6_hours VCAP


title: MSA206_I17_niclosamide 0.03_uM 6_hours VCAP


title: MSA206_I20_DIHYDROSTILBESTROL 0_uM 6_hours 3182-2-4


title: MSA206_I22_Chlorpromazine 0.03_uM 6_hours 3182-2-4


title: MSA206_I13_3-acetamidocoumarin 0.01_uM 6_hours VCAP


title: MSA206_I16_DMSO NA 6_hours 3182-2-4


title: MSA206_I09_TRANYLCYPROMINE HYDROCHLORIDE 3_uM 6_hours VCAP


title: MSA206_I14_3-acetamidocoumarin 0.01_uM 6_hours 3182-2-4


title: MSA206_I12_suloctidil 1_uM 6_hours 3182-2-4


title: MSA206_I11_suloctidil 1_uM 6_hours VCAP


title: MSA206_I10_TRANYLCYPROMINE HYDROCHLORIDE 3_uM 6_hours 3182-2-4


title: MSA206_I08_TIAGABINE 1_uM 6_hours 3182-2-4


title: MSA206_I02_DMSO NA 6_hours 3182-2-4


title: MSA206_I06_nefopam 0.3_uM 6_hours 3182-2-4


title: MSA206_I04_EPLERENONE 3_uM 6_hours 3182-2-4


title: MSA206_I07_TIAGABINE 1_uM 6_hours VCAP


title: MSA206_H24_DMSO NA 6_hours 449-2-12


title: MSA206_I03_EPLERENONE 3_uM 6_hours VCAP


title: MSA206_I01_DMSO NA 6_hours VCAP


title: MSA206_H22_chenodeoxycholic acid 10_uM 6_hours 449-2-12

value: chenodeoxycholic acid


title: MSA206_H21_chenodeoxycholic acid 10_uM 6_hours 2484-2-A


title: MSA206_H20_ESTRONE 0.03_uM 6_hours 449-2-12

value: ESTRONE


title: MSA206_H19_ESTRONE 0.03_uM 6_hours 2484-2-A


title: MSA206_I05_nefopam 0.3_uM 6_hours VCAP


title: MSA206_H16_MEMANTINE HYDROCHLORIDE 0.01_uM 6_hours 449-2-12

value: MEMANTINE HYDROCHLORIDE


title: MSA206_H17_GLAXO:GR247538 1_uM 6_hours 2484-2-A


title: MSA206_H18_GLAXO:GR247538 1_uM 6_hours 449-2-12


title: MSA206_H14_BMS-250904 0.3_uM 6_hours 449-2-12


title: MSA206_H13_BMS-250904 0.3_uM 6_hours 2484-2-A


title: MSA206_H12_CONESSINE 0.3_uM 6_hours 449-2-12

value: CONESSINE


title: MSA206_H15_MEMANTINE HYDROCHLORIDE 0.01_uM 6_hours 2484-2-A

value: test


title: MSA206_H09_trichostatin A 0.13_uM 6_hours 2484-2-A

value: trichostatin A

value: poscon


title: MSA206_H04_Quetiapine 0.3_uM 6_hours 449-2-12

value: Quetiapine


title: MSA206_H03_Quetiapine 0.3_uM 6_hours 2484-2-A


title: MSA206_H11_CONESSINE 0.3_uM 6_hours 2484-2-A


title: MSA206_H06_HARMINE HYDROCHLORIDE 0.3_uM 6_hours 449-2-12

value: HARMINE HYDROCHLORIDE


title: MSA206_H10_trichostatin A 0.13_uM 6_hours 449-2-12


title: MSA206_H23_DMSO NA 6_hours 2484-2-A

value: DMSO


title: MSA206_H08_KANPAULLONE 0.1_uM 6_hours 449-2-12

value: KANPAULLONE


title: MSA206_G21_chenodeoxycholic acid 10_uM 6_hours VCAP


title: MSA206_H01_CM ZA 0576 1_uM 6_hours 2484-2-A

value: CM ZA 0576


title: MSA206_G22_chenodeoxycholic acid 10_uM 6_hours 3182-2-4


title: MSA206_G23_DMSO NA 6_hours VCAP

value: vehicle


title: MSA206_G24_DMSO NA 6_hours 3182-2-4


title: MSA206_G20_ESTRONE 0.03_uM 6_hours 3182-2-4


title: MSA206_G19_ESTRONE 0.03_uM 6_hours VCAP


title: MSA206_H05_HARMINE HYDROCHLORIDE 0.3_uM 6_hours 2484-2-A


title: MSA206_G18_GLAXO:GR247538 1_uM 6_hours 3182-2-4


title: MSA206_G17_GLAXO:GR247538 1_uM 6_hours VCAP


title: MSA206_H02_CM ZA 0576 1_uM 6_hours 449-2-12


title: MSA206_G15_MEMANTINE HYDROCHLORIDE 0.01_uM 6_hours VCAP


title: MSA206_G13_BMS-250904 0.3_uM 6_hours VCAP


title: MSA206_G12_CONESSINE 0.3_uM 6_hours 3182-2-4


title: MSA206_G10_trichostatin A 0.13_uM 6_hours 3182-2-4


title: MSA206_G05_HARMINE HYDROCHLORIDE 0.3_uM 6_hours VCAP


title: MSA206_G07_KANPAULLONE 0.1_uM 6_hours VCAP


title: MSA206_G03_Quetiapine 0.3_uM 6_hours VCAP


title: MSA206_G11_CONESSINE 0.3_uM 6_hours VCAP


title: MSA206_G16_MEMANTINE HYDROCHLORIDE 0.01_uM 6_hours 3182-2-4


title: MSA206_G02_CM ZA 0576 1_uM 6_hours 3182-2-4


title: MSA206_F24_LY379268 0.13_uM 6_hours 449-2-12


title: MSA206_G08_KANPAULLONE 0.1_uM 6_hours 3182-2-4


title: MSA206_G01_CM ZA 0576 1_uM 6_hours VCAP


title: MSA206_G09_trichostatin A 0.13_uM 6_hours VCAP


title: MSA206_G14_BMS-250904 0.3_uM 6_hours 3182-2-4


title: MSA206_F21_NALOXONE HYDROCHLORIDE 0_uM 6_hours 2484-2-A

value: NALOXONE HYDROCHLORIDE


title: MSA206_F23_LY379268 0.13_uM 6_hours 2484-2-A


title: MSA206_H07_KANPAULLONE 0.1_uM 6_hours 2484-2-A


title: MSA206_F19_EQUILENIN 0.03_uM 6_hours 2484-2-A

value: EQUILENIN


title: MSA206_F20_EQUILENIN 0.03_uM 6_hours 449-2-12


title: MSA206_F18_DMSO NA 6_hours 449-2-12


title: MSA206_F16_NOGESTREL 0.01_uM 6_hours 449-2-12

value: NOGESTREL


title: MSA206_F15_NOGESTREL 0.01_uM 6_hours 2484-2-A


title: MSA206_G04_Quetiapine 0.3_uM 6_hours 3182-2-4


title: MSA206_F13_salsolidin 10_uM 6_hours 2484-2-A

value: salsolidin


title: MSA206_F14_salsolidin 10_uM 6_hours 449-2-12


title: MSA206_F22_NALOXONE HYDROCHLORIDE 0_uM 6_hours 449-2-12


title: MSA206_F11_DMSO NA 6_hours 2484-2-A


title: MSA206_F12_DMSO NA 6_hours 449-2-12


title: MSA206_G06_HARMINE HYDROCHLORIDE 0.3_uM 6_hours 3182-2-4


title: MSA206_F17_DMSO NA 6_hours 2484-2-A


title: MSA206_F10_VANDETANIB 0.3_uM 6_hours 449-2-12

value: VANDETANIB


title: MSA206_F08_URAPIDIL, 5-METHYL- 0.1_uM 6_hours 449-2-12

value: URAPIDIL, 5-METHYL-


title: MSA206_F09_VANDETANIB 0.3_uM 6_hours 2484-2-A


title: MSA206_F07_URAPIDIL, 5-METHYL- 0.1_uM 6_hours 2484-2-A


title: MSA206_F06_LAMIVUDINE 3_uM 6_hours 449-2-12

value: LAMIVUDINE


title: MSA206_E24_LY379268 0.13_uM 6_hours 3182-2-4


title: MSA206_F04_MDL 29951 3_uM 6_hours 449-2-12


title: MSA206_F01_diltiazem 0.3_uM 6_hours 2484-2-A

value: diltiazem


title: MSA206_F02_diltiazem 0.3_uM 6_hours 449-2-12

value: test


title: MSA206_F03_MDL 29951 3_uM 6_hours 2484-2-A


title: MSA206_E22_NALOXONE HYDROCHLORIDE 0_uM 6_hours 3182-2-4


title: MSA206_E23_LY379268 0.13_uM 6_hours VCAP

value: VCAP


title: MSA206_E18_DMSO NA 6_hours 3182-2-4


title: MSA206_E21_NALOXONE HYDROCHLORIDE 0_uM 6_hours VCAP


title: MSA206_F05_LAMIVUDINE 3_uM 6_hours 2484-2-A


title: MSA206_E20_EQUILENIN 0.03_uM 6_hours 3182-2-4


title: MSA206_E13_salsolidin 10_uM 6_hours VCAP


title: MSA206_E09_VANDETANIB 0.3_uM 6_hours VCAP


title: MSA206_E16_NOGESTREL 0.01_uM 6_hours 3182-2-4


title: MSA206_E14_salsolidin 10_uM 6_hours 3182-2-4


title: MSA206_E19_EQUILENIN 0.03_uM 6_hours VCAP


title: MSA206_E17_DMSO NA 6_hours VCAP


title: MSA206_E15_NOGESTREL 0.01_uM 6_hours VCAP


title: MSA206_E08_URAPIDIL, 5-METHYL- 0.1_uM 6_hours 3182-2-4


title: MSA206_E06_LAMIVUDINE 3_uM 6_hours 3182-2-4


title: MSA206_E05_LAMIVUDINE 3_uM 6_hours VCAP


title: MSA206_E12_DMSO NA 6_hours 3182-2-4


title: MSA206_D22_SB 43152 1_uM 6_hours 449-2-12


title: MSA206_E11_DMSO NA 6_hours VCAP


title: MSA206_D23_quinpirole 0.13_uM 6_hours 2484-2-A

value: quinpirole


title: MSA206_E10_VANDETANIB 0.3_uM 6_hours 3182-2-4


title: MSA206_D20_BENZYLOXYCARBONYL-L-GLYCYL-L-PHENYLALANYL-L-PHENYLALANYL-L-TYROSINEBENZYL ESTER 1_uM 6_hours 449-2-12


title: MSA206_E07_URAPIDIL, 5-METHYL- 0.1_uM 6_hours VCAP


title: MSA206_E01_diltiazem 0.3_uM 6_hours VCAP


title: MSA206_E03_MDL 29951 3_uM 6_hours VCAP


title: MSA206_D17_Ziprasidone 0.03_uM 6_hours 2484-2-A

value: Ziprasidone


title: MSA206_D19_BENZYLOXYCARBONYL-L-GLYCYL-L-PHENYLALANYL-L-PHENYLALANYL-L-TYROSINEBENZYL ESTER 1_uM 6_hours 2484-2-A


title: MSA206_D18_Ziprasidone 0.03_uM 6_hours 449-2-12


title: MSA206_E02_diltiazem 0.3_uM 6_hours 3182-2-4


title: MSA206_D10_DMSO NA 6_hours 449-2-12


title: MSA206_D13_tanespimycin NA 6_hours 2484-2-A

value: tanespimycin

value: poscon


title: MSA206_D16_mebendazole 0.3_uM 6_hours 449-2-12

value: mebendazole


title: MSA206_D24_quinpirole 0.13_uM 6_hours 449-2-12


title: MSA206_D14_tanespimycin NA 6_hours 449-2-12


title: MSA206_D21_SB 43152 1_uM 6_hours 2484-2-A


title: MSA206_D11_DIPHENYLAMINOTRIAZINE 3_uM 6_hours 2484-2-A

value: DIPHENYLAMINOTRIAZINE


title: MSA206_D15_mebendazole 0.3_uM 6_hours 2484-2-A


title: MSA206_D12_DIPHENYLAMINOTRIAZINE 3_uM 6_hours 449-2-12


title: MSA206_D06_DMSO NA 6_hours 449-2-12

value: DMSO

value: vehicle


title: MSA206_D07_phenelzine 0_uM 6_hours 2484-2-A

value: phenelzine


title: MSA206_D03_DORZOLAMIDE HYDROCHLORIDE 0.1_uM 6_hours 2484-2-A

value: DORZOLAMIDE HYDROCHLORIDE


title: MSA206_D09_DMSO NA 6_hours 2484-2-A


title: MSA206_D05_DMSO NA 6_hours 2484-2-A


title: MSA206_D02_PERCEPTIN 0.3_uM 6_hours 449-2-12

value: PERCEPTIN


title: MSA206_D04_DORZOLAMIDE HYDROCHLORIDE 0.1_uM 6_hours 449-2-12


title: MSA206_D08_phenelzine 0_uM 6_hours 449-2-12


title: MSA206_D01_PERCEPTIN 0.3_uM 6_hours 2484-2-A


title: MSA206_C21_SB 43152 1_uM 6_hours VCAP


title: MSA206_C24_quinpirole 0.13_uM 6_hours 3182-2-4


title: MSA206_C22_SB 43152 1_uM 6_hours 3182-2-4


title: MSA206_C23_quinpirole 0.13_uM 6_hours VCAP


title: MSA206_C17_Ziprasidone 0.03_uM 6_hours VCAP


title: MSA206_C11_DIPHENYLAMINOTRIAZINE 3_uM 6_hours VCAP


title: MSA206_C19_BENZYLOXYCARBONYL-L-GLYCYL-L-PHENYLALANYL-L-PHENYLALANYL-L-TYROSINEBENZYL ESTER 1_uM 6_hours VCAP


title: MSA206_C14_tanespimycin NA 6_hours 3182-2-4


title: MSA206_C03_DORZOLAMIDE HYDROCHLORIDE 0.1_uM 6_hours VCAP


title: MSA206_C12_DIPHENYLAMINOTRIAZINE 3_uM 6_hours 3182-2-4


title: MSA206_C15_mebendazole 0.3_uM 6_hours VCAP


title: MSA206_C20_BENZYLOXYCARBONYL-L-GLYCYL-L-PHENYLALANYL-L-PHENYLALANYL-L-TYROSINEBENZYL ESTER 1_uM 6_hours 3182-2-4


title: MSA206_C04_DORZOLAMIDE HYDROCHLORIDE 0.1_uM 6_hours 3182-2-4


title: MSA206_C16_mebendazole 0.3_uM 6_hours 3182-2-4


title: MSA206_C05_DMSO NA 6_hours VCAP


title: MSA206_C13_tanespimycin NA 6_hours VCAP


title: MSA206_C08_phenelzine 0_uM 6_hours 3182-2-4


title: MSA206_C09_DMSO NA 6_hours VCAP


title: MSA206_C06_DMSO NA 6_hours 3182-2-4


title: MSA206_B22_DMSO NA 6_hours 449-2-12


title: MSA206_C10_DMSO NA 6_hours 3182-2-4


title: MSA206_B23_PODOPHYLLOTOXIN 0.01_uM 6_hours 2484-2-A

value: PODOPHYLLOTOXIN


title: MSA206_C01_PERCEPTIN 0.3_uM 6_hours VCAP


title: MSA206_C07_phenelzine 0_uM 6_hours VCAP


title: MSA206_C18_Ziprasidone 0.03_uM 6_hours 3182-2-4


title: MSA206_C02_PERCEPTIN 0.3_uM 6_hours 3182-2-4


title: MSA206_B24_PODOPHYLLOTOXIN 0.01_uM 6_hours 449-2-12


title: MSA206_B19_POTASSIUM ESTRONE SULFATE 0.03_uM 6_hours 2484-2-A

value: POTASSIUM ESTRONE SULFATE


title: MSA206_B20_POTASSIUM ESTRONE SULFATE 0.03_uM 6_hours 449-2-12


title: MSA206_B21_DMSO NA 6_hours 2484-2-A


title: MSA206_A20_POTASSIUM ESTRONE SULFATE 0.03_uM 6_hours 3182-2-4


title: MSA206_B18_NALTREXONE HYDROCHLORIDE 0_uM 6_hours 449-2-12

value: NALTREXONE HYDROCHLORIDE


title: MSA206_B10_lycorine 3_uM 6_hours 449-2-12

value: lycorine


title: MSA206_B14_SPIRONOLACTONE 0.1_uM 6_hours 449-2-12

value: SPIRONOLACTONE

value: test


title: MSA206_B15_RISPERIDONE 0.03_uM 6_hours 2484-2-A

value: RISPERIDONE


title: MSA206_B12_UNC0638 0.1_uM 6_hours 449-2-12


title: MSA206_B04_NORFLOXACIN 10_uM 6_hours 449-2-12

value: NORFLOXACIN


title: MSA206_B13_SPIRONOLACTONE 0.1_uM 6_hours 2484-2-A


title: MSA206_B09_lycorine 3_uM 6_hours 2484-2-A


title: MSA206_B07_ANDROSTERONE 0.03_uM 6_hours 2484-2-A

value: ANDROSTERONE


title: MSA206_B06_QUIPAZINE, N-METHYL-, DIMALEATE 0.03_uM 6_hours 449-2-12

value: QUIPAZINE, N-METHYL-, DIMALEATE


title: MSA206_A22_DMSO NA 6_hours 3182-2-4


title: MSA206_A18_NALTREXONE HYDROCHLORIDE 0_uM 6_hours 3182-2-4


title: MSA206_B05_QUIPAZINE, N-METHYL-, DIMALEATE 0.03_uM 6_hours 2484-2-A


title: MSA206_B08_ANDROSTERONE 0.03_uM 6_hours 449-2-12


title: MSA206_B03_NORFLOXACIN 10_uM 6_hours 2484-2-A


title: MSA206_A23_PODOPHYLLOTOXIN 0.01_uM 6_hours VCAP

value: VCAP


title: MSA206_B11_UNC0638 0.1_uM 6_hours 2484-2-A


title: MSA206_B16_RISPERIDONE 0.03_uM 6_hours 449-2-12


title: MSA206_A21_DMSO NA 6_hours VCAP


title: MSA206_A19_POTASSIUM ESTRONE SULFATE 0.03_uM 6_hours VCAP


title: MSA206_B17_NALTREXONE HYDROCHLORIDE 0_uM 6_hours 2484-2-A


title: MSA206_A17_NALTREXONE HYDROCHLORIDE 0_uM 6_hours VCAP


title: MSA206_E04_MDL 29951 3_uM 6_hours 3182-2-4


title: MSA206_A24_PODOPHYLLOTOXIN 0.01_uM 6_hours 3182-2-4


title: MSA206_A16_RISPERIDONE 0.03_uM 6_hours 3182-2-4


title: MSA206_A14_SPIRONOLACTONE 0.1_uM 6_hours 3182-2-4


title: MSA206_A15_RISPERIDONE 0.03_uM 6_hours VCAP


title: MSA206_A13_SPIRONOLACTONE 0.1_uM 6_hours VCAP


title: MSA206_A08_ANDROSTERONE 0.03_uM 6_hours 3182-2-4


title: MSA206_A07_ANDROSTERONE 0.03_uM 6_hours VCAP


title: MSA205_P24_Nimodipine 1.34_uM 6_hours 2011-3-12

value: Nimodipine


title: MSA205_P21_MOCLOBEMIDE 10_uM 6_hours 2607-3-1

value: MOCLOBEMIDE


title: MSA205_P22_MOCLOBEMIDE 10_uM 6_hours 2011-3-12


title: MSA206_A11_UNC0638 0.1_uM 6_hours VCAP


title: MSA206_A06_QUIPAZINE, N-METHYL-, DIMALEATE 0.03_uM 6_hours 3182-2-4


title: MSA205_P23_Nimodipine 1.34_uM 6_hours 2607-3-1


title: MSA205_P20_ETIFENIN 1_uM 6_hours 2011-3-12

value: ETIFENIN


title: MSA206_A04_NORFLOXACIN 10_uM 6_hours 3182-2-4


title: MSA206_A09_lycorine 3_uM 6_hours VCAP


title: MSA206_A12_UNC0638 0.1_uM 6_hours 3182-2-4


title: MSA206_A10_lycorine 3_uM 6_hours 3182-2-4


title: MSA205_P16_ETHOXZOLAMIDE 0_uM 6_hours 2011-3-12

value: ETHOXZOLAMIDE


title: MSA205_P19_ETIFENIN 1_uM 6_hours 2607-3-1


title: MSA205_P10_CETOCYCLINE' 'A-13428' 0.3_uM 6_hours 2011-3-12

value: CETOCYCLINE' 'A-13428'


title: MSA206_A05_QUIPAZINE, N-METHYL-, DIMALEATE 0.03_uM 6_hours VCAP


title: MSA205_P14_DMSO NA 6_hours 2011-3-12

value: DMSO

value: vehicle


title: MSA205_P18_GLIPIZIDE 0_uM 6_hours 2011-3-12

value: GLIPIZIDE


title: MSA206_A03_NORFLOXACIN 10_uM 6_hours VCAP


title: MSA205_P12_BUFLOMEDIL HYDROCHLORIDE 1_uM 6_hours 2011-3-12

value: BUFLOMEDIL HYDROCHLORIDE


title: MSA205_P09_CETOCYCLINE' 'A-13428' 0.3_uM 6_hours 2607-3-1


title: MSA205_P11_BUFLOMEDIL HYDROCHLORIDE 1_uM 6_hours 2607-3-1


title: MSA205_P17_GLIPIZIDE 0_uM 6_hours 2607-3-1


title: MSA205_P13_DMSO NA 6_hours 2607-3-1


title: MSA205_P15_ETHOXZOLAMIDE 0_uM 6_hours 2607-3-1


title: MSA205_P08_VATALANIB 1_uM 6_hours 2011-3-12

value: VATALANIB


title: MSA205_P06_BUPROPION HYDROCHLORIDE 0.3_uM 6_hours 2011-3-12

value: BUPROPION HYDROCHLORIDE


title: MSA205_P07_VATALANIB 1_uM 6_hours 2607-3-1

value: test


title: MSA205_P05_BUPROPION HYDROCHLORIDE 0.3_uM 6_hours 2607-3-1


title: MSA205_P01_ESTRIOL 0.03_uM 6_hours 2607-3-1

value: ESTRIOL


title: MSA205_P04_DMSO NA 6_hours 2011-3-12


title: MSA205_P02_ESTRIOL 0.03_uM 6_hours 2011-3-12


title: MSA205_O24_Nimodipine 1.34_uM 6_hours 553-3-1


title: MSA205_O22_MOCLOBEMIDE 10_uM 6_hours 553-3-1


title: MSA205_O21_MOCLOBEMIDE 10_uM 6_hours HT29


title: MSA205_O19_ETIFENIN 1_uM 6_hours HT29


title: MSA205_O17_GLIPIZIDE 0_uM 6_hours HT29


title: MSA205_O16_ETHOXZOLAMIDE 0_uM 6_hours 553-3-1


title: MSA205_O14_DMSO NA 6_hours 553-3-1


title: MSA205_P03_DMSO NA 6_hours 2607-3-1


title: MSA205_O15_ETHOXZOLAMIDE 0_uM 6_hours HT29


title: MSA205_O13_DMSO NA 6_hours HT29


title: MSA205_O23_Nimodipine 1.34_uM 6_hours HT29


title: MSA205_O18_GLIPIZIDE 0_uM 6_hours 553-3-1


title: MSA205_O08_VATALANIB 1_uM 6_hours 553-3-1


title: MSA205_O06_BUPROPION HYDROCHLORIDE 0.3_uM 6_hours 553-3-1


title: MSA205_O05_BUPROPION HYDROCHLORIDE 0.3_uM 6_hours HT29


title: MSA205_O20_ETIFENIN 1_uM 6_hours 553-3-1


title: MSA205_O10_CETOCYCLINE' 'A-13428' 0.3_uM 6_hours 553-3-1


title: MSA205_O09_CETOCYCLINE' 'A-13428' 0.3_uM 6_hours HT29


title: MSA205_O11_BUFLOMEDIL HYDROCHLORIDE 1_uM 6_hours HT29


title: MSA205_O07_VATALANIB 1_uM 6_hours HT29


title: MSA205_O04_DMSO NA 6_hours 553-3-1


title: MSA205_O12_BUFLOMEDIL HYDROCHLORIDE 1_uM 6_hours 553-3-1


title: MSA205_O03_DMSO NA 6_hours HT29


title: MSA205_N20_anisomycin 0.1_uM 6_hours 2011-3-12

value: anisomycin


title: MSA205_O01_ESTRIOL 0.03_uM 6_hours HT29


title: MSA205_N23_BAY K8644 1.34_uM 6_hours 2607-3-1

value: BAY K8644


title: MSA205_O02_ESTRIOL 0.03_uM 6_hours 553-3-1


title: MSA205_N18_trichostatin A 0.13_uM 6_hours 2011-3-12

value: trichostatin A

value: poscon


title: MSA205_N24_BAY K8644 1.34_uM 6_hours 2011-3-12


title: MSA205_N21_CLOZAPINE 0.1_uM 6_hours 2607-3-1

value: CLOZAPINE


title: MSA205_N17_trichostatin A 0.13_uM 6_hours 2607-3-1


title: MSA205_N14_Aripiprazole 0.03_uM 6_hours 2011-3-12

value: Aripiprazole


title: MSA205_N19_anisomycin 0.1_uM 6_hours 2607-3-1


title: MSA205_N22_CLOZAPINE 0.1_uM 6_hours 2011-3-12


title: MSA205_N16_WB-4101 HYDROCHLORIDE 0_uM 6_hours 2011-3-12

value: WB-4101 HYDROCHLORIDE


title: MSA205_N15_WB-4101 HYDROCHLORIDE 0_uM 6_hours 2607-3-1


title: MSA205_N10_ILOPERIDONE 0.01_uM 6_hours 2011-3-12

value: ILOPERIDONE


title: MSA205_N13_Aripiprazole 0.03_uM 6_hours 2607-3-1


title: MSA205_N07_DMSO NA 6_hours 2607-3-1


title: MSA205_N08_DMSO NA 6_hours 2011-3-12


title: MSA205_M24_BAY K8644 1.34_uM 6_hours 553-3-1


title: MSA205_N12_SORAFENIB 0.03_uM 6_hours 2011-3-12

value: SORAFENIB


title: MSA205_N11_SORAFENIB 0.03_uM 6_hours 2607-3-1


title: MSA205_N01_BOSUTINIB 0.01_uM 6_hours 2607-3-1

value: BOSUTINIB


title: MSA205_N09_ILOPERIDONE 0.01_uM 6_hours 2607-3-1


title: MSA205_M23_BAY K8644 1.34_uM 6_hours HT29


title: MSA205_N02_BOSUTINIB 0.01_uM 6_hours 2011-3-12


title: MSA205_M10_ILOPERIDONE 0.01_uM 6_hours 553-3-1


title: MSA205_M17_trichostatin A 0.13_uM 6_hours HT29


title: MSA205_N04_GT-2394 RAC 10_uM 6_hours 2011-3-12

value: GT-2394 RAC


title: MSA205_M18_trichostatin A 0.13_uM 6_hours 553-3-1


title: MSA205_M19_anisomycin 0.1_uM 6_hours HT29


title: MSA205_M22_CLOZAPINE 0.1_uM 6_hours 553-3-1


title: MSA205_M20_anisomycin 0.1_uM 6_hours 553-3-1


title: MSA205_M15_WB-4101 HYDROCHLORIDE 0_uM 6_hours HT29


title: MSA205_M11_SORAFENIB 0.03_uM 6_hours HT29


title: MSA205_M13_Aripiprazole 0.03_uM 6_hours HT29


title: MSA205_N03_GT-2394 RAC 10_uM 6_hours 2607-3-1


title: MSA205_N06_DL-thiorphan 0.3_uM 6_hours 2011-3-12

value: DL-thiorphan


title: MSA205_M12_SORAFENIB 0.03_uM 6_hours 553-3-1


title: MSA205_M21_CLOZAPINE 0.1_uM 6_hours HT29


title: MSA205_M09_ILOPERIDONE 0.01_uM 6_hours HT29


title: MSA205_M14_Aripiprazole 0.03_uM 6_hours 553-3-1


title: MSA205_N05_DL-thiorphan 0.3_uM 6_hours 2607-3-1


title: MSA205_M16_WB-4101 HYDROCHLORIDE 0_uM 6_hours 553-3-1


title: MSA205_M08_DMSO NA 6_hours 553-3-1

value: DMSO

value: vehicle


title: MSA205_M05_DL-thiorphan 0.3_uM 6_hours HT29


title: MSA205_M06_DL-thiorphan 0.3_uM 6_hours 553-3-1


title: MSA205_M07_DMSO NA 6_hours HT29


title: MSA205_M03_GT-2394 RAC 10_uM 6_hours HT29


title: MSA205_L20_DMSO NA 6_hours 2011-3-12


title: MSA205_L19_DMSO NA 6_hours 2607-3-1


title: MSA205_L22_N6-CYCLOPENTYLADENOSINE 1_uM 6_hours 2011-3-12


title: MSA205_L24_MDL100907 0.67_uM 6_hours 2011-3-12


title: MSA205_M04_GT-2394 RAC 10_uM 6_hours 553-3-1


title: MSA205_L18_celastrol 10_uM 6_hours 2011-3-12

value: celastrol


title: MSA205_L17_celastrol 10_uM 6_hours 2607-3-1

value: test


title: MSA205_L07_METHYLPARABEN 10_uM 6_hours 2607-3-1

value: METHYLPARABEN


title: MSA205_L12_norethindrone 0.01_uM 6_hours 2011-3-12

value: norethindrone


title: MSA205_L21_N6-CYCLOPENTYLADENOSINE 1_uM 6_hours 2607-3-1


title: MSA205_L14_IOFETAMINE HYDROCHLORIDE 10_uM 6_hours 2011-3-12

value: IOFETAMINE HYDROCHLORIDE


title: MSA205_L10_SB-242235 0.3_uM 6_hours 2011-3-12


title: MSA205_L13_IOFETAMINE HYDROCHLORIDE 10_uM 6_hours 2607-3-1


title: MSA205_L06_CORTICOSTERONE 0.01_uM 6_hours 2011-3-12

value: CORTICOSTERONE


title: MSA205_L15_GABAZINE 1_uM 6_hours 2607-3-1

value: GABAZINE


title: MSA205_L05_CORTICOSTERONE 0.01_uM 6_hours 2607-3-1


title: MSA205_M01_BOSUTINIB 0.01_uM 6_hours HT29


title: MSA205_L23_MDL100907 0.67_uM 6_hours 2607-3-1


title: MSA205_L16_GABAZINE 1_uM 6_hours 2011-3-12


title: MSA205_L08_METHYLPARABEN 10_uM 6_hours 2011-3-12


title: MSA205_L11_norethindrone 0.01_uM 6_hours 2607-3-1


title: MSA205_L09_SB-242235 0.3_uM 6_hours 2607-3-1


title: MSA205_K24_MDL100907 0.67_uM 6_hours 553-3-1


title: MSA205_L04_tanespimycin NA 6_hours 2011-3-12

value: tanespimycin

value: poscon


title: MSA205_L03_tanespimycin NA 6_hours 2607-3-1


title: MSA205_L01_MAFENIDE HYDROCHLORIDE 0_uM 6_hours 2607-3-1

value: MAFENIDE HYDROCHLORIDE


title: MSA205_L02_MAFENIDE HYDROCHLORIDE 0_uM 6_hours 2011-3-12


title: MSA205_M02_BOSUTINIB 0.01_uM 6_hours 553-3-1